<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34071457</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Physical Exercise-Induced Myokines in Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5795</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22115795</ELocationID><Abstract><AbstractText>Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are disorders characterized by progressive degeneration of the nervous system. Currently, there is no disease-modifying treatments for most NDs. Meanwhile, numerous studies conducted on human and animal models over the past decades have showed that exercises had beneficial effects on NDs. Inter-tissue communication by myokine, a peptide produced and secreted by skeletal muscles during exercise, is thought to be an important underlying mechanism for the advantages. Here, we reviewed studies about the effects of myokines regulated by exercise on NDs and their mechanisms. Myokines could exert beneficial effects on NDs through a variety of regulatory mechanisms, including cell survival, neurogenesis, neuroinflammation, proteostasis, oxidative stress, and protein modification. Studies on exercise-induced myokines are expected to provide a novel strategy for treating NDs, for which there are no adequate treatments nowadays. To date, only a few myokines have been investigated for their effects on NDs and studies on mechanisms involved in them are in their infancy. Therefore, future studies are needed to discover more myokines and test their effects on NDs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Banseok</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Konkuk University, Seoul 05029, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Myeongcheol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Konkuk University, Seoul 05029, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Youngjae</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Konkuk University, Seoul 05029, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Won</LastName><ForeName>So-Yoon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Konkuk University, Seoul 05029, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Korea Hemp Institute, Konkuk University, Seoul 05029, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Kyoung Sang</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0002-3277-8269</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, Konkuk University, Seoul 05029, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Korea Hemp Institute, Konkuk University, Seoul 05029, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2017-A019-0582</GrantID><Agency>Konkuk University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">exercise</Keyword><Keyword MajorTopicYN="N">muscle&#x2013;brain axis</Keyword><Keyword MajorTopicYN="N">myokines</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34071457</ArticleId><ArticleId IdType="pmc">PMC8198301</ArticleId><ArticleId IdType="doi">10.3390/ijms22115795</ArticleId><ArticleId IdType="pii">ijms22115795</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004;10:S10&#x2013;S17. doi: 10.1038/nm1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1066</ArticleId><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler A.D., Dhillon P., Shorter J. Neurodegenerative disease: Models, mechanisms, and a new hope. Dis. Model. Mech. 2017;10:499&#x2013;502. doi: 10.1242/dmm.030205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.030205</ArticleId><ArticleId IdType="pmc">PMC5451177</ArticleId><ArticleId IdType="pubmed">28468935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugger B.N., Dickson D.W. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 2017;9:a028035. doi: 10.1101/cshperspect.a028035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028035</ArticleId><ArticleId IdType="pmc">PMC5495060</ArticleId><ArticleId IdType="pubmed">28062563</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J.J., Chin J., Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773. doi: 10.1038/nature05289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05289</ArticleId><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007;39:44&#x2013;84. doi: 10.1016/j.biocel.2006.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.07.001</ArticleId><ArticleId IdType="pubmed">16978905</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918&#x2013;934. doi: 10.1016/j.cell.2010.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.016</ArticleId><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Jim&#xe9;nez E.P., Flor-Garc&#xed;a M., Terreros-Roncal J., R&#xe1;bano A., Cafini F., Pallas-Bazarra N., &#xc1;vila J., Llorens-Mart&#xed;n M. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer&#x2019;s disease. Nat. Med. 2019;25:554&#x2013;560. doi: 10.1038/s41591-019-0375-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0375-9</ArticleId><ArticleId IdType="pubmed">30911133</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C., Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 2018;21:1332&#x2013;1340. doi: 10.1038/s41593-018-0235-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0235-9</ArticleId><ArticleId IdType="pmc">PMC6432913</ArticleId><ArticleId IdType="pubmed">30250260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006;7:710&#x2013;723. doi: 10.1038/nrn1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker F.O. Huntington&#x2019;s disease. Lancet. 2007;369:218&#x2013;228. doi: 10.1016/S0140-6736(07)60111-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60111-1</ArticleId><ArticleId IdType="pubmed">17240289</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanis L. &#x3b1;-Synuclein in Parkinson&#x2019;s disease. Cold Spring Harb. Perspect. Med. 2012;2:a009399. doi: 10.1101/cshperspect.a009399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a009399</ArticleId><ArticleId IdType="pmc">PMC3281589</ArticleId><ArticleId IdType="pubmed">22355802</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster C.P., Smith E.F., Shaw P.J., De Vos K.J. Protein homeostasis in amyotrophic lateral sclerosis: Therapeutic opportunities? Front. Mol. Neurosci. 2017;10:123. doi: 10.3389/fnmol.2017.00123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00123</ArticleId><ArticleId IdType="pmc">PMC5411428</ArticleId><ArticleId IdType="pubmed">28512398</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman C.W., Berchtold N.C., Christie L.-A. Exercise builds brain health: Key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30:464&#x2013;472. doi: 10.1016/j.tins.2007.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2007.06.011</ArticleId><ArticleId IdType="pubmed">17765329</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral D.F., Rice J., Morris T.P., Rundek T., Pascual-Leone A., Gomes-Osman J. Exercise for brain health: An investigation into the underlying mechanisms guided by dose. Neurotherapeutics. 2019;16:580&#x2013;599. doi: 10.1007/s13311-019-00749-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00749-w</ArticleId><ArticleId IdType="pmc">PMC6694330</ArticleId><ArticleId IdType="pubmed">31197642</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeper S.A., Gomez-Pinilla F., Choi J., Cotman C. Exercise and brain neurotrophins. Nature. 1995;373:109. doi: 10.1038/373109a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/373109a0</ArticleId><ArticleId IdType="pubmed">7816089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman C.W., Berchtold N.C. Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 2002;25:295&#x2013;301. doi: 10.1016/S0166-2236(02)02143-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(02)02143-4</ArticleId><ArticleId IdType="pubmed">12086747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaynman S., Ying Z., Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur. J. Neurosci. 2004;20:2580&#x2013;2590. doi: 10.1111/j.1460-9568.2004.03720.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03720.x</ArticleId><ArticleId IdType="pubmed">15548201</ArticleId></ArticleIdList></Reference><Reference><Citation>Handschin C., Spiegelman B.M. The role of exercise and PGC1&#x3b1; in inflammation and chronic disease. Nature. 2008;454:463&#x2013;469. doi: 10.1038/nature07206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07206</ArticleId><ArticleId IdType="pmc">PMC2587487</ArticleId><ArticleId IdType="pubmed">18650917</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela P.L., Castillo-Garc&#xed;a A., Morales J.S., de la Villa P., Hampel H., Emanuele E., Lista S., Lucia A. Exercise benefits on Alzheimer&#x2019;s disease: State-of-the-science. Ageing Res. Rev. 2020:101108. doi: 10.1016/j.arr.2020.101108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101108</ArticleId><ArticleId IdType="pubmed">32561386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlskog J.E., Geda Y.E., Graff-Radford N.R., Petersen R.C. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin. Proc. 2011;86:876&#x2013;884. doi: 10.4065/mcp.2011.0252.</Citation><ArticleIdList><ArticleId IdType="doi">10.4065/mcp.2011.0252</ArticleId><ArticleId IdType="pmc">PMC3258000</ArticleId><ArticleId IdType="pubmed">21878600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cass S.P. Alzheimer&#x2019;s disease and exercise: A literature review. Curr. Sports Med. Rep. 2017;16:19&#x2013;22. doi: 10.1249/JSR.0000000000000332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/JSR.0000000000000332</ArticleId><ArticleId IdType="pubmed">28067736</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Q., Lin M.-S., Tzeng I. Relationship between exercise and Alzheimer&#x2019;s disease: A narrative literature review. Front. Neurosci. 2020;14:131. doi: 10.3389/fnins.2020.00131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00131</ArticleId><ArticleId IdType="pmc">PMC7113559</ArticleId><ArticleId IdType="pubmed">32273835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham C., O&#x2019;Sullivan R., Caserotti P., Tully M.A. Consequences of physical inactivity in older adults: A systematic review of reviews and meta-analyses. Scand. J. Med. Sci. Sports. 2020;30:816&#x2013;827. doi: 10.1111/sms.13616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sms.13616</ArticleId><ArticleId IdType="pubmed">32020713</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Costa Daniele T.M., de Bruin P.F.C., de Matos R.S., de Bruin G.S., Junior C.M.C., de Bruin V.M.S. Exercise effects on brain and behavior in healthy mice, Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease model&#x2014;A systematic review and meta-analysis. Behav. Brain Res. 2020;383:112488. doi: 10.1016/j.bbr.2020.112488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2020.112488</ArticleId><ArticleId IdType="pubmed">31991178</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin V.A., Richards S.H., Taylor R.S., Taylor A.H., Campbell J.L. The effectiveness of exercise interventions for people with Parkinson&#x2019;s disease: A systematic review and meta-analysis. Mov. Disord. 2008;23:631&#x2013;640. doi: 10.1002/mds.21922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21922</ArticleId><ArticleId IdType="pubmed">18181210</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabandla M., Kellaway L., Gibson A.S.C., Russell V.A. Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. Metab. Brain Dis. 2004;19:43&#x2013;50. doi: 10.1023/B:MEBR.0000027416.13070.c3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:MEBR.0000027416.13070.c3</ArticleId><ArticleId IdType="pubmed">15214505</ArticleId></ArticleIdList></Reference><Reference><Citation>Howells F.M., Russell V.A., Mabandla M.V., Kellaway L.A. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson&#x2019;s disease. Behav. Brain Res. 2005;165:210&#x2013;220. doi: 10.1016/j.bbr.2005.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2005.06.044</ArticleId><ArticleId IdType="pubmed">16159673</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulton N.P., Muir G.D. Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-parkinsonian rats. Exp. Neurol. 2005;193:181&#x2013;197. doi: 10.1016/j.expneurol.2004.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.12.006</ArticleId><ArticleId IdType="pubmed">15817277</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;dell S.J., Gross N.B., Fricks A.N., Casiano B.D., Nguyen T.B., Marshall J.F. Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection. Neuroscience. 2007;144:1141&#x2013;1151. doi: 10.1016/j.neuroscience.2006.10.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.10.042</ArticleId><ArticleId IdType="pubmed">17157992</ArticleId></ArticleIdList></Reference><Reference><Citation>Mabandla M.V., Kellaway L.A., Daniels W.M.U., Russell V.A. Effect of exercise on dopamine neuron survival in prenatally stressed rats. Metab. Brain Dis. 2009;24:525&#x2013;539. doi: 10.1007/s11011-009-9161-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-009-9161-6</ArticleId><ArticleId IdType="pmc">PMC2863025</ArticleId><ArticleId IdType="pubmed">19844780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz N.E., Rao A.K., Kegelmeyer D., Kloos A., Busse M., Hartel L., Carrier J., Quinn L. Physical therapy and exercise interventions in Huntington&#x2019;s disease: A mixed methods systematic review. J. Huntingt. Dis. 2017;6:217&#x2013;235. doi: 10.3233/JHD-170260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-170260</ArticleId><ArticleId IdType="pmc">PMC5676854</ArticleId><ArticleId IdType="pubmed">28968244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitkanou S., Della Gatta P., Foletta V., Russell A. The role of exercise as a non-pharmacological therapeutic approach for amyotrophic lateral sclerosis: Beneficial or detrimental? Front. Neurol. 2019;10:783. doi: 10.3389/fneur.2019.00783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00783</ArticleId><ArticleId IdType="pmc">PMC6652799</ArticleId><ArticleId IdType="pubmed">31379732</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrochano S., Blanco G., Williams D., Wettstein J., Simon M., Kumar S., Moir L., Agnew T., Stewart M., Landman A., et al. A genetic modifier suggests that endurance exercise exacerbates Huntington&#x2019;s disease. Hum. Mol. Genet. 2018;27:1723&#x2013;1731. doi: 10.1093/hmg/ddy077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy077</ArticleId><ArticleId IdType="pmc">PMC5932560</ArticleId><ArticleId IdType="pubmed">29509900</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederiksen K.S., Gjerum L., Waldemar G., Hasselbalch S.G. Effects of physical exercise on Alzheimer&#x2019;s disease biomarkers: A systematic review of intervention studies. J. Alzheimers Dis. 2018;61:359&#x2013;372. doi: 10.3233/JAD-170567.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170567</ArticleId><ArticleId IdType="pubmed">29154278</ArticleId></ArticleIdList></Reference><Reference><Citation>Playle R., Dimitropoulou P., Kelson M., Quinn L., Busse M. Exercise Interventions in Huntington&#x2019;s Disease: An Individual Patient Data Meta-Analysis. Mov. Disord. Clin. Pract. 2019;6:567&#x2013;575. doi: 10.1002/mdc3.12809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.12809</ArticleId><ArticleId IdType="pmc">PMC6749801</ArticleId><ArticleId IdType="pubmed">31538091</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen B.K. Physical activity and muscle-brain crosstalk. Nat. Rev. Endocrinol. 2019;15:383&#x2013;392. doi: 10.1038/s41574-019-0174-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-019-0174-x</ArticleId><ArticleId IdType="pubmed">30837717</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal L.G., Lopes M.A., Batista M.L., Jr. Physical exercise-induced myokines and muscle-adipose tissue crosstalk: A review of current knowledge and the implications for health and metabolic diseases. Front. Physiol. 2018;9:1307. doi: 10.3389/fphys.2018.01307.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.01307</ArticleId><ArticleId IdType="pmc">PMC6166321</ArticleId><ArticleId IdType="pubmed">30319436</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen B.K., Steensberg A., Fischer C., Keller C., Keller P., Plomgaard P., Febbraio M., Saltin B. Searching for the exercise factor: Is IL-6 a candidate? J. Muscle Res. Cell Motil. 2003;24:113&#x2013;119. doi: 10.1023/A:1026070911202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1026070911202</ArticleId><ArticleId IdType="pubmed">14609022</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitham M., Febbraio M.A. The ever-expanding myokinome: Discovery challenges and therapeutic implications. Nat. Rev. Drug. Discov. 2016;15:719. doi: 10.1038/nrd.2016.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.153</ArticleId><ArticleId IdType="pubmed">27616294</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon H.Y., Becke A., Berron D., Becker B., Sah N., Benoni G., Janke E., Lubejko S.T., Greig N.H., Mattison J.A., et al. Running-Induced systemic cathepsin B secretion is associated with memory function. Cell Metab. 2016;24:332&#x2013;340. doi: 10.1016/j.cmet.2016.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.05.025</ArticleId><ArticleId IdType="pmc">PMC6029441</ArticleId><ArticleId IdType="pubmed">27345423</ArticleId></ArticleIdList></Reference><Reference><Citation>Morland C., Andersson K.A., Haugen &#xd8;.P., Hadzic A., Kleppa L., Gille A., Rinholm J.E., Palibrk V., Diget E.H., Kennedy L.H., et al. Exercise induces cerebral VEGF and angiogenesis via the lactate receptor HCAR1. Nat. Commun. 2017;8:1&#x2013;9. doi: 10.1038/ncomms15557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15557</ArticleId><ArticleId IdType="pmc">PMC5457513</ArticleId><ArticleId IdType="pubmed">28534495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostr&#xf6;m P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., Rasbach K.A., Bostr&#xf6;m E.A., Choi J.H., Long J.Z., et al. A PGC1-&#x3b1;-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463&#x2013;468. doi: 10.1038/nature10777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10777</ArticleId><ArticleId IdType="pmc">PMC3522098</ArticleId><ArticleId IdType="pubmed">22237023</ArticleId></ArticleIdList></Reference><Reference><Citation>Febbraio M.A., Hiscock N., Sacchetti M., Fischer C.P., Pedersen B.K. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes. 2004;53:1643&#x2013;1648. doi: 10.2337/diabetes.53.7.1643.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.53.7.1643</ArticleId><ArticleId IdType="pubmed">15220185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizgier M.L., Fern&#xe1;ndez-Verdejo R., Cherfan J., Pinget M., Bouzakri K., Galgani J.E. Insights on the role of putative muscle-derived factors on pancreatic beta cell function. Front. Physiol. 2019;10:1024. doi: 10.3389/fphys.2019.01024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.01024</ArticleId><ArticleId IdType="pmc">PMC6694406</ArticleId><ArticleId IdType="pubmed">31440170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatemoto K., Hosoya M., Habata Y., Fujii R., Kakegawa T., Zou M.-X., Kawamata Y., Fukusumi S., Hinuma S., Kitada C., et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 1998;251:471&#x2013;476. doi: 10.1006/bbrc.1998.9489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1998.9489</ArticleId><ArticleId IdType="pubmed">9792798</ArticleId></ArticleIdList></Reference><Reference><Citation>Antushevich H., W&#xf3;jcik M. Apelin in disease. Clin. Chim. Acta. 2018;483:241&#x2013;248. doi: 10.1016/j.cca.2018.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2018.05.012</ArticleId><ArticleId IdType="pubmed">29750964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurowska P., Barbe A., R&#xf3;&#x17c;ycka M., Chmieli&#x144;ska J., Dupont J., Rak A. Apelin in reproductive physiology and pathology of different species: A critical review. Int. J. Endocrinol. 2018;2018 doi: 10.1155/2018/9170480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/9170480</ArticleId><ArticleId IdType="pmc">PMC6011052</ArticleId><ArticleId IdType="pubmed">29977292</ArticleId></ArticleIdList></Reference><Reference><Citation>Besse-Patin A., Montastier E., Vinel C., Castan-Laurell I., Louche K., Dray C., Daviaud D., Mir L., Marques M., Thalamas C., et al. Effect of endurance training on skeletal muscle myokine expression in obese men: Identification of apelin as a novel myokine. Int. J. Obes. 2014;38:707&#x2013;713. doi: 10.1038/ijo.2013.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijo.2013.158</ArticleId><ArticleId IdType="pubmed">23979219</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinel C., Lukjanenko L., Batut A., Deleruyelle S., Pradere J.-P., Le Gonidec S., Dortignac A., Geoffre N., Pereira O., Karaz S., et al. The exerkine apelin reverses age-associated sarcopenia. Nat. Med. 2018;24:1360&#x2013;1371. doi: 10.1038/s41591-018-0131-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0131-6</ArticleId><ArticleId IdType="pubmed">30061698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocka M.B., Pietraszek-Gremplewicz K., Nowak D. The role of apelin in cardiovascular diseases, obesity and cancer. Front. Physiol. 2018;9:557. doi: 10.3389/fphys.2018.00557.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00557</ArticleId><ArticleId IdType="pmc">PMC5974534</ArticleId><ArticleId IdType="pubmed">29875677</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell L.A., Agrawal A., Sabnekar P., Dichter M.A., Lynch D.R., Kolson D.L. Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury. J. Neurochem. 2007;102:1905&#x2013;1917. doi: 10.1111/j.1471-4159.2007.04645.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04645.x</ArticleId><ArticleId IdType="pubmed">17767704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng X.J., Yu S.P., Zhang L., Wei L. Neuroprotective effect of the endogenous neural peptide apelin in cultured mouse cortical neurons. Exp. Cell Res. 2010;316:1773&#x2013;1783. doi: 10.1016/j.yexcr.2010.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2010.02.005</ArticleId><ArticleId IdType="pmc">PMC3155990</ArticleId><ArticleId IdType="pubmed">20152832</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng B., Chen J., Bai B., Xin Q. Neuroprotection of apelin and its signaling pathway. Peptides. 2012;37:171&#x2013;173. doi: 10.1016/j.peptides.2012.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2012.07.012</ArticleId><ArticleId IdType="pubmed">22820556</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Q., Cheng B., Pan Y., Liu H., Yang C., Chen J., Bai B. Neuroprotective effects of apelin-13 on experimental ischemic stroke through suppression of inflammation. Peptides. 2015;63:55&#x2013;62. doi: 10.1016/j.peptides.2014.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2014.09.016</ArticleId><ArticleId IdType="pubmed">25278489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao H., Yang X., Huang Y., Qiu H., Huang G., Xiao H., Kuai J. The neuroprotective effect of apelin-13 in a mouse model of intracerebral hemorrhage. Neurosci. Lett. 2016;628:219&#x2013;224. doi: 10.1016/j.neulet.2016.06.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2016.06.046</ArticleId><ArticleId IdType="pubmed">27343409</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalantaripour T.P., Esmaeili-Mahani S., Sheibani V., Asadi-Shekaari M., Pasban-Aliabadi H. Anticonvulsant and neuroprotective effects of apelin-13 on pentylenetetrazole-induced seizures in male rats. Biomed. Pharmacother. 2016;84:258&#x2013;263. doi: 10.1016/j.biopha.2016.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2016.09.048</ArticleId><ArticleId IdType="pubmed">27664950</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Li T., Gao L., Zheng J., Yan J., Zhang J., Shao A. Apelin-13/APJ system attenuates early brain injury via suppression of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation and oxidative stress in a AMPK-dependent manner after subarachnoid hemorrhage in rats. J. Neuroinflamm. 2019;16:1&#x2013;14. doi: 10.1186/s12974-019-1620-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1620-3</ArticleId><ArticleId IdType="pmc">PMC6889224</ArticleId><ArticleId IdType="pubmed">31791369</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghparast E., Esmaeili-Mahani S., Abbasnejad M., Sheibani V. Apelin-13 ameliorates cognitive impairments in 6-hydroxydopamine-induced substantia nigra lesion in rats. Neuropeptides. 2018;68:28&#x2013;35. doi: 10.1016/j.npep.2018.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2018.01.001</ArticleId><ArticleId IdType="pubmed">29329678</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Liu H., Ji B., Wang Z., Wang C., Yang C., Pan Y., Chen J., Cheng B., Bai B. Apelin-13 attenuates ER stress-associated apoptosis induced by MPP+ in SH-SY5Y cells. Int. J. Mol. Med. 2018;42:1732&#x2013;1740. doi: 10.3892/ijmm.2018.3719.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2018.3719</ArticleId><ArticleId IdType="pubmed">29901077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouresmaeili-Babaki E., Esmaeili-Mahani S., Abbasnejad M., Ravan H. Protective effect of neuropeptide apelin-13 on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y dopaminergic cells: Involvement of its antioxidant and antiapoptotic properties. Rejuvenation Res. 2018;21:162&#x2013;167. doi: 10.1089/rej.2017.1951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2017.1951</ArticleId><ArticleId IdType="pubmed">28782414</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminyavari S., Zahmatkesh M., Farahmandfar M., Khodagholi F., Dargahi L., Zarrindast M.-R. Protective role of Apelin-13 on amyloid &#x3b2;25&#x2013;35-induced memory deficit; Involvement of autophagy and apoptosis process. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2019;89:322&#x2013;334. doi: 10.1016/j.pnpbp.2018.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2018.10.005</ArticleId><ArticleId IdType="pubmed">30296470</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminyavari S., Zahmatkesh M., Khodagholi F., Sanati M. Anxiolytic impact of Apelin-13 in a rat model of Alzheimer&#x2019;s disease: Involvement of glucocorticoid receptor and FKBP5. Peptides. 2019;118:170102. doi: 10.1016/j.peptides.2019.170102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2019.170102</ArticleId><ArticleId IdType="pubmed">31199948</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H., Xiang Y., Qu X., Liu H., Liu C., Li G., Han L., Qin X. Apelin-13 suppresses neuroinflammation against cognitive deficit in a streptozotocin-induced rat model of Alzheimer&#x2019;s disease through activation of BDNF-TrkB signaling pathway. Front. Pharmacol. 2019;10:395. doi: 10.3389/fphar.2019.00395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00395</ArticleId><ArticleId IdType="pmc">PMC6477031</ArticleId><ArticleId IdType="pubmed">31040784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Dou S., Jiang Y., Bai B., Chen J., Wang C., Cheng B. Apelin-36 exerts the cytoprotective effect against MPP+-induced cytotoxicity in SH-SY5Y cells through PI3K/Akt/mTOR autophagy pathway. Life Sci. 2019;224:95&#x2013;108. doi: 10.1016/j.lfs.2019.03.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.03.047</ArticleId><ArticleId IdType="pubmed">30905782</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P., Wang Y., Chen L., Song N., Xie J. Apelin-13 Protects Dopaminergic Neurons against Rotenone&#x2014;Induced Neurotoxicity through the AMPK/mTOR/ULK-1 Mediated Autophagy Activation. Int. J. Mol. Sci. 2020;21:8376. doi: 10.3390/ijms21218376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218376</ArticleId><ArticleId IdType="pmc">PMC7664695</ArticleId><ArticleId IdType="pubmed">33171641</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasseri B., Zareian P., Alizade H. Apelin attenuates streptozotocin-induced learning and memory impairment by modulating necroptosis signaling pathway. Int. Immunopharmacol. 2020;84:106546. doi: 10.1016/j.intimp.2020.106546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106546</ArticleId><ArticleId IdType="pubmed">32413735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai A., Kinjo T., Ishihara R., Sakai I., Ishimaru Y., Yoshioka Y., Yamamuro A., Ishige K., Ito Y., Maeda S. Apelin deficiency accelerates the progression of amyotrophic lateral sclerosis. PLoS ONE. 2011;6:e23968. doi: 10.1371/journal.pone.0023968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023968</ArticleId><ArticleId IdType="pmc">PMC3161091</ArticleId><ArticleId IdType="pubmed">21887354</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H., Poo M.-M. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 2013;14:7&#x2013;23. doi: 10.1038/nrn3379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3379</ArticleId><ArticleId IdType="pubmed">23254191</ArticleId></ArticleIdList></Reference><Reference><Citation>Barde Y.-A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1:549&#x2013;553. doi: 10.1002/j.1460-2075.1982.tb01207.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1982.tb01207.x</ArticleId><ArticleId IdType="pmc">PMC553086</ArticleId><ArticleId IdType="pubmed">7188352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37:1553&#x2013;1561. doi: 10.1016/S0028-3908(98)00141-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3908(98)00141-5</ArticleId><ArticleId IdType="pubmed">9886678</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder D.K., Scharfman H.E. Brain-Derived neurotrophic factor. Growth Factors. 2004;22:123&#x2013;131. doi: 10.1080/08977190410001723308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08977190410001723308</ArticleId><ArticleId IdType="pmc">PMC2504526</ArticleId><ArticleId IdType="pubmed">15518235</ArticleId></ArticleIdList></Reference><Reference><Citation>Hing B., Sathyaputri L., Potash J.B. A comprehensive review of genetic and epigenetic mechanisms that regulate BDNF expression and function with relevance to major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2018;177:143&#x2013;167. doi: 10.1002/ajmg.b.32616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.32616</ArticleId><ArticleId IdType="pubmed">29243873</ArticleId></ArticleIdList></Reference><Reference><Citation>Squinto S.P., Stitt T.N., Aldrich T.H., Davis S., Blanco S.M., RadzieJewski C., Glass D.J., Masiakowski P., Furth M.E., Valenzuela D.M., et al. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell. 1991;65:885&#x2013;893. doi: 10.1016/0092-8674(91)90395-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(91)90395-F</ArticleId><ArticleId IdType="pubmed">1710174</ArticleId></ArticleIdList></Reference><Reference><Citation>Castr&#xe9;n E., Rantam&#xe4;ki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 2010;70:289&#x2013;297. doi: 10.1002/dneu.20758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.20758</ArticleId><ArticleId IdType="pubmed">20186711</ArticleId></ArticleIdList></Reference><Reference><Citation>Etnier J.L., Wideman L., Labban J.D., Piepmeier A.T., Pendleton D.M., Dvorak K.K., Becofsky K. The effects of acute exercise on memory and brain-derived neurotrophic factor (BDNF) J. Sport Exerc. Psychol. 2016;38:331&#x2013;340. doi: 10.1123/jsep.2015-0335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/jsep.2015-0335</ArticleId><ArticleId IdType="pubmed">27385735</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh J.J., Tschakovsky M.E. Exercise and circulating BDNF: Mechanisms of release and implications for the design of exercise interventions. Appl. Physiol. Nutr. Metab. 2018;43:1095&#x2013;1104. doi: 10.1139/apnm-2018-0192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/apnm-2018-0192</ArticleId><ArticleId IdType="pubmed">29775542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Brobst D., Chan W.S., Tse M.C.L., Herlea-Pana O., Ahuja P., Bi X., Zaw A.M., Kwong Z.S.W., Jia W.-H., et al. Muscle-Generated BDNF is a sexually dimorphic myokine that controls metabolic flexibility. Sci. Signal. 2019;12:eaau1468. doi: 10.1126/scisignal.aau1468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aau1468</ArticleId><ArticleId IdType="pmc">PMC7219567</ArticleId><ArticleId IdType="pubmed">31409756</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulgenzi G., Hong Z., Tomassoni-Ardori F., Barella L.F., Becker J., Barrick C., Swing D., Yanpallewar S., St Croix B., Wess J., et al. Novel metabolic role for BDNF in pancreatic &#x3b2;-cell insulin secretion. Nat. Commun. 2020;11:1&#x2013;18. doi: 10.1038/s41467-020-15833-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15833-5</ArticleId><ArticleId IdType="pmc">PMC7181656</ArticleId><ArticleId IdType="pubmed">32327658</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.H., Bylykbashi E., Chatila Z.K., Lee S.W., Pulli B., Clemenson G.D., Kim E., Rompala A., Oram M.K., Asselin C., et al. Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer&#x2019;s mouse model. Science. 2018;361 doi: 10.1126/science.aan8821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan8821</ArticleId><ArticleId IdType="pmc">PMC6149542</ArticleId><ArticleId IdType="pubmed">30190379</ArticleId></ArticleIdList></Reference><Reference><Citation>Real C.C., Ferreira A.F.B., Chaves-Kirsten G.P., Torrao A.S., Pires R.S., Britto L.R.G. BDNF receptor blockade hinders the beneficial effects of exercise in a rat model of Parkinson&#x2019;s disease. Neuroscience. 2013;237:118&#x2013;129. doi: 10.1016/j.neuroscience.2013.01.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.01.060</ArticleId><ArticleId IdType="pubmed">23396085</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer&#x2019;s disease. Neuron. 1991;7:695&#x2013;702. doi: 10.1016/0896-6273(91)90273-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(91)90273-3</ArticleId><ArticleId IdType="pubmed">1742020</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin X.-Y., Cao C., Cawley N.X., Liu T.-T., Yuan J., Loh Y.P., Cheng Y. Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer&#x2019;s disease: A meta-analysis study (N = 7277) Mol. Psychiatry. 2017;22:312&#x2013;320. doi: 10.1038/mp.2016.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.62</ArticleId><ArticleId IdType="pubmed">27113997</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein G., Beiser A.S., Choi S.H., Preis S.R., Chen T.C., Vorgas D., Au R., Pikula A., Wolf P.A., DeStefano A.L., et al. Serum brain-derived neurotrophic factor and the risk for dementia: The Framingham Heart Study. JAMA Neurol. 2014;71:55&#x2013;61. doi: 10.1001/jamaneurol.2013.4781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4781</ArticleId><ArticleId IdType="pmc">PMC4056186</ArticleId><ArticleId IdType="pubmed">24276217</ArticleId></ArticleIdList></Reference><Reference><Citation>Arancibia S., Silhol M., Mouliere F., Meffre J., H&#xf6;llinger I., Maurice T., Tapia-Arancibia L. Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol. Dis. 2008;31:316&#x2013;326. doi: 10.1016/j.nbd.2008.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.05.012</ArticleId><ArticleId IdType="pubmed">18585459</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., M&#xfc;ller F.-J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 2009;106:13594&#x2013;13599. doi: 10.1073/pnas.0901402106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0901402106</ArticleId><ArticleId IdType="pmc">PMC2715325</ArticleId><ArticleId IdType="pubmed">19633196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer&#x2019;s disease. Nat. Med. 2009;15:331&#x2013;337. doi: 10.1038/nm.1912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1912</ArticleId><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara A.H., Mateling M., Kovacs I., Wang L., Eggert S., Rockenstein E., Koo E.H., Masliah E., Tuszynski M.H. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J. Neurosci. 2013;33:15596&#x2013;15602. doi: 10.1523/JNEUROSCI.5195-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5195-12.2013</ArticleId><ArticleId IdType="pmc">PMC3782628</ArticleId><ArticleId IdType="pubmed">24068826</ArticleId></ArticleIdList></Reference><Reference><Citation>de Pins B., Cifuentes-D&#xed;az C., Farah A.T., L&#xf3;pez-Molina L., Montalban E., Sancho-Balsells A., L&#xf3;pez A., Gin&#xe9;s S., Delgado-Garc&#xed;a J.M., Alberch J., et al. Conditional BDNF delivery from astrocytes rescues memory deficits, spine density, and synaptic properties in the 5xFAD mouse model of Alzheimer disease. J. Neurosci. 2019;39:2441&#x2013;2458. doi: 10.1523/JNEUROSCI.2121-18.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2121-18.2019</ArticleId><ArticleId IdType="pmc">PMC6435824</ArticleId><ArticleId IdType="pubmed">30700530</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257&#x2013;269. doi: 10.1016/S0092-8674(03)00035-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00035-7</ArticleId><ArticleId IdType="pubmed">12553913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y.Y., Villemagne V.L., Laws S.M., Pietrzak R.H., Snyder P.J., Ames D., Ellis K.A., Harrington K., Rembach A., Martins R.N., et al. APOE and BDNF polymorphisms moderate amyloid &#x3b2;-related cognitive decline in preclinical Alzheimer&#x2019;s disease. Mol. Psychiatry. 2015;20:1322&#x2013;1328. doi: 10.1038/mp.2014.123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2014.123</ArticleId><ArticleId IdType="pmc">PMC4759101</ArticleId><ArticleId IdType="pubmed">25288138</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N., Ren J., Damm A., Mont&#xe9;-Rubio G., Boada M., Ruiz A., Ramirez A., Jessen F., D&#xfc;zel E., G&#xf3;mez O.R., et al. The BDNF Val66Met SNP modulates the association between &#x3b2;-amyloid and hippocampal disconnection in Alzheimer&#x2019;s disease. Mol. Psychiatry. 2021;26:614&#x2013;628. doi: 10.1038/s41380-019-0404-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0404-6</ArticleId><ArticleId IdType="pmc">PMC6754794</ArticleId><ArticleId IdType="pubmed">30899092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman C., Hofer M., Barde Y.-A., Juhasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991;350:230&#x2013;232. doi: 10.1038/350230a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/350230a0</ArticleId><ArticleId IdType="pubmed">2005978</ArticleId></ArticleIdList></Reference><Reference><Citation>Altar C.A., Boylan C.B., Jackson C., Hershenson S., Miller J., Wiegand S.J., Lindsay R.M., Hyman C. Brain-Derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. Sci. USA. 1992;89:11347&#x2013;11351. doi: 10.1073/pnas.89.23.11347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.23.11347</ArticleId><ArticleId IdType="pmc">PMC50547</ArticleId><ArticleId IdType="pubmed">1454818</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Negro A., Facci L., Toso R.D. Brain-Derived neurotrophic factor selectively rescues mesencephalic dopaminergic neurons from 2, 4, 5-trihydroxyphenylalanine-induced injury. J. Neurosci. Res. 1993;34:478&#x2013;487. doi: 10.1002/jnr.490340413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490340413</ArticleId><ArticleId IdType="pubmed">8097267</ArticleId></ArticleIdList></Reference><Reference><Citation>Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. USA. 1994;91:5104&#x2013;5108. doi: 10.1073/pnas.91.11.5104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.11.5104</ArticleId><ArticleId IdType="pmc">PMC43940</ArticleId><ArticleId IdType="pubmed">8197193</ArticleId></ArticleIdList></Reference><Reference><Citation>Levivier M., Przedborski S., Bencsics C., Kang U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson&#x2019;s disease. J. Neurosci. 1995;15:7810&#x2013;7820. doi: 10.1523/JNEUROSCI.15-12-07810.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.15-12-07810.1995</ArticleId><ArticleId IdType="pmc">PMC6577965</ArticleId><ArticleId IdType="pubmed">8613721</ArticleId></ArticleIdList></Reference><Reference><Citation>Galpern W.R., Frim D.M., Tatter S.B., Altar C.A., Beal M.F., Isacson O. Cell-Mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant. 1996;5:225&#x2013;232. doi: 10.1177/096368979600500211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096368979600500211</ArticleId><ArticleId IdType="pubmed">8689033</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F., Yang W., Florio J.B., Rockenstein E., Spencer B., Orain X.M., Dong S.X., Li H., Chen X., Sung K., et al. Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson&#x2019;s disease. Sci. Rep. 2017;7:1&#x2013;13. doi: 10.1038/s41598-017-04232-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04232-4</ArticleId><ArticleId IdType="pmc">PMC5478665</ArticleId><ArticleId IdType="pubmed">28634349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S.S., Zhang Z., Liu X., Manfredsson F.P., Benskey M.J., Cao X., Xu J., Sun Y.E., Ye K. TrkB neurotrophic activities are blocked by &#x3b1;-synuclein, triggering dopaminergic cell death in Parkinson&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2017;114:10773&#x2013;10778. doi: 10.1073/pnas.1713969114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1713969114</ArticleId><ArticleId IdType="pmc">PMC5635931</ArticleId><ArticleId IdType="pubmed">28923922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mort J.S., Buttle D.J. Cathepsin b. Int. J. Biochem. Cell Biol. 1997;29:715&#x2013;720. doi: 10.1016/S1357-2725(96)00152-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1357-2725(96)00152-5</ArticleId><ArticleId IdType="pubmed">9251238</ArticleId></ArticleIdList></Reference><Reference><Citation>Man S.M., Kanneganti T.-D. Regulation of lysosomal dynamics and autophagy by CTSB/cathepsin B. Autophagy. 2016;12:2504&#x2013;2505. doi: 10.1080/15548627.2016.1239679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2016.1239679</ArticleId><ArticleId IdType="pmc">PMC5173259</ArticleId><ArticleId IdType="pubmed">27786577</ArticleId></ArticleIdList></Reference><Reference><Citation>Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007;6:60&#x2013;64. doi: 10.4161/cc.6.1.3669.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.6.1.3669</ArticleId><ArticleId IdType="pubmed">17245112</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreyer H.C., Fujita S., Cadenas J.G., Chinkes D.L., Volpi E., Rasmussen B.B. Resistance exercise increases AMPK activity and reduces 4E-BP1 phosphorylation and protein synthesis in human skeletal muscle. J. Physiol. 2006;576:613&#x2013;624. doi: 10.1113/jphysiol.2006.113175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2006.113175</ArticleId><ArticleId IdType="pmc">PMC1890364</ArticleId><ArticleId IdType="pubmed">16873412</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill H.M., Holloway G.P., Steinberg G.R. AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: Implications for obesity. Mol. Cell. Endocrinol. 2013;366:135&#x2013;151. doi: 10.1016/j.mce.2012.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2012.06.019</ArticleId><ArticleId IdType="pubmed">22750049</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Rosa A., Solana E., Corpas R., Bartr&#xe9;s-Faz D., Pall&#xe0;s M., Vina J., Sanfeliu C., Gomez-Cabrera M.C. Long-Term exercise training improves memory in middle-aged men and modulates peripheral levels of BDNF and Cathepsin, B. Sci. Rep. 2019;9:1&#x2013;11. doi: 10.1038/s41598-019-40040-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-40040-8</ArticleId><ArticleId IdType="pmc">PMC6399244</ArticleId><ArticleId IdType="pubmed">30833610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller-Steiner S., Zhou Y., Arai H., Roberson E.D., Sun B., Chen J., Wang X., Yu G., Esposito L., Mucke L., et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer&#x2019;s disease. Neuron. 2006;51:703&#x2013;714. doi: 10.1016/j.neuron.2006.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.07.027</ArticleId><ArticleId IdType="pubmed">16982417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Zhou Y., Halabisky B., Lo I., Cho S.-H., Mueller-Steiner S., Devidze N., Wang X., Grubb A., Gan L. Cystatin C-cathepsin B axis regulates amyloid &#x3b2; levels and associated neuronal deficits in an animal model of Alzheimer&#x2019;s disease. Neuron. 2008;60:247&#x2013;257. doi: 10.1016/j.neuron.2008.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.10.001</ArticleId><ArticleId IdType="pmc">PMC2755563</ArticleId><ArticleId IdType="pubmed">18957217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Sun B., Zhou Y., Grubb A., Gan L. Cathepsin B degrades amyloid-&#x3b2; in mice expressing wild-type human amyloid precursor protein. J. Biol. Chem. 2012;287:39834&#x2013;39841. doi: 10.1074/jbc.M112.371641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.371641</ArticleId><ArticleId IdType="pmc">PMC3501032</ArticleId><ArticleId IdType="pubmed">23024364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauritzen I., Pardossi-Piquard R., Bourgeois A., Pagnotta S., Biferi M.-G., Barkats M., Lacor P., Klein W., Bauer C., Checler F. Intraneuronal aggregation of the &#x3b2;-CTF fragment of APP (C99) induces A&#x3b2;-independent lysosomal-autophagic pathology. Acta Neuropathol. 2016;132:257&#x2013;276. doi: 10.1007/s00401-016-1577-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1577-6</ArticleId><ArticleId IdType="pmc">PMC4947121</ArticleId><ArticleId IdType="pubmed">27138984</ArticleId></ArticleIdList></Reference><Reference><Citation>Embury C.M., Dyavarshetty B., Lu Y., Wiederin J.L., Ciborowski P., Gendelman H.E., Kiyota T. Cathepsin B improves &#xdf;-amyloidosis and learning and memory in models of Alzheimer&#x2019;s disease. J. Neuroimmune Pharmacol. 2017;12:340&#x2013;352. doi: 10.1007/s11481-016-9721-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-016-9721-6</ArticleId><ArticleId IdType="pmc">PMC5405105</ArticleId><ArticleId IdType="pubmed">27966067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang J., Estick C.M., Ikonne U.S., Butler D., Pait M.C., Elliott L.H., Ruiz S., Smith K., Rentschler K.M., Mundell C., et al. The role of lysosomes in a broad disease-modifying approach evaluated across transgenic mouse models of Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease and models of mild cognitive impairment. Int. J. Mol. Sci. 2019;20:4432. doi: 10.3390/ijms20184432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184432</ArticleId><ArticleId IdType="pmc">PMC6770842</ArticleId><ArticleId IdType="pubmed">31505809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J. A new class of membrane-bound chemokine with a CX 3 C motif. Nature. 1997;385:640&#x2013;644. doi: 10.1038/385640a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/385640a0</ArticleId><ArticleId IdType="pubmed">9024663</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Lloyd C., Zhou H., Dolich S., Deeds J., Gonzalo J.-A., Vath J., Gosselin M., Ma J., Dussault B., et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387:611&#x2013;617. doi: 10.1038/42491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42491</ArticleId><ArticleId IdType="pubmed">9177350</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., Kakizaki M., Takagi S., Nomiyama H., Schall T.J., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521&#x2013;530. doi: 10.1016/S0092-8674(00)80438-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80438-9</ArticleId><ArticleId IdType="pubmed">9390561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona A.E., Pioro E.P., Sasse M.E., Kostenko V., Cardona S.M., Dijkstra I.M., Huang D., Kidd G., Dombrowski S., Dutta R., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006;9:917&#x2013;924. doi: 10.1038/nn1715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1715</ArticleId><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Garton K.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., Raines E.W. Tumor necrosis factor-&#x3b1;-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1) J. Biol. Chem. 2001;276:37993&#x2013;38001. doi: 10.1074/jbc.M106434200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M106434200</ArticleId><ArticleId IdType="pubmed">11495925</ArticleId></ArticleIdList></Reference><Reference><Citation>Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., Hartmann D., Fahrenholz F., Postina R., Matthews V., et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102:1186&#x2013;1195. doi: 10.1182/blood-2002-12-3775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-12-3775</ArticleId><ArticleId IdType="pubmed">12714508</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones B.A., Beamer M., Ahmed S. Fractalkine/CX3CL1: A potential new target for inflammatory diseases. Mol. Interv. 2010;10:263. doi: 10.1124/mi.10.5.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mi.10.5.3</ArticleId><ArticleId IdType="pmc">PMC3002219</ArticleId><ArticleId IdType="pubmed">21045240</ArticleId></ArticleIdList></Reference><Reference><Citation>Peake J.M., Della Gatta P., Suzuki K., Nieman D.C. Cytokine expression and secretion by skeletal muscle cells: Regulatory mechanisms and exercise effects. Exerc. Immunol. Rev. 2015;21:8&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25826432</ArticleId></ArticleIdList></Reference><Reference><Citation>Catoire M., Mensink M., Kalkhoven E., Schrauwen P., Kersten S. Identification of human exercise-induced myokines using secretome analysis. Physiol. Genom. 2014;46:256&#x2013;267. doi: 10.1152/physiolgenomics.00174.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00174.2013</ArticleId><ArticleId IdType="pubmed">24520153</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Gatta P.A., Cameron-Smith D., Peake J.M. Acute resistance exercise increases the expression of chemotactic factors within skeletal muscle. Eur. J. Appl. Physiol. 2014;114:2157&#x2013;2167. doi: 10.1007/s00421-014-2936-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00421-014-2936-4</ArticleId><ArticleId IdType="pubmed">24968868</ArticleId></ArticleIdList></Reference><Reference><Citation>Catoire M., Kersten S. The search for exercise factors in humans. FASEB J. 2015;29:1615&#x2013;1628. doi: 10.1096/fj.14-263699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14-263699</ArticleId><ArticleId IdType="pubmed">25593123</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf6;mberg A., Olsson K., Dijksterhuis J.P., Rullman E., Schulte G., Gustafsson T. CX3CL1&#x2014;A macrophage chemoattractant induced by a single bout of exercise in human skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016;310:R297&#x2013;R304. doi: 10.1152/ajpregu.00236.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00236.2015</ArticleId><ArticleId IdType="pubmed">26632602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R.M., Liu L., Cardona A.E. Chemokines and chemokine receptors: Multipurpose players in neuroinflammation. Int. Rev. Neurobiol. 2007;82:187&#x2013;204. doi: 10.1016/S0074-7742(07)82010-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0074-7742(07)82010-1</ArticleId><ArticleId IdType="pubmed">17678962</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R.-S., Yang X., Chen Z.-G., Lu M.-O., Morris C., Winblad B., Zhu J. Decreased Fractalkine and Increased IP-10 Expression in Aged Brain of APP swe Transgenic Mice. Neurochem. Res. 2008;33:1085&#x2013;1089. doi: 10.1007/s11064-007-9554-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9554-z</ArticleId><ArticleId IdType="pubmed">18095157</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S.-H., Sun B., Zhou Y., Kauppinen T.M., Halabisky B., Wes P., Ransohoff R.M., Gan L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2011;286:32713&#x2013;32722. doi: 10.1074/jbc.M111.254268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.254268</ArticleId><ArticleId IdType="pmc">PMC3173153</ArticleId><ArticleId IdType="pubmed">21771791</ArticleId></ArticleIdList></Reference><Reference><Citation>Perea J.R., Lle&#xf3; A., Alcolea D., Fortea J., &#xc1;vila J., Bol&#xf3;s M. Decreased CX3CL1 levels in the cerebrospinal fluid of patients with Alzheimer&#x2019;s disease. Front. Neurosci. 2018;12:609. doi: 10.3389/fnins.2018.00609.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00609</ArticleId><ArticleId IdType="pmc">PMC6137321</ArticleId><ArticleId IdType="pubmed">30245615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Prieto M., Guti&#xe9;rrez I.L., Garc&#xed;a-Bueno B., Caso J.R., Leza J.C., Ortega-Hern&#xe1;ndez A., G&#xf3;mez-Garre D., Madrigal J.L.M. Microglial CX3CR1 production increases in Alzheimer&#x2019;s disease and is regulated by noradrenaline. Glia. 2021;69:73&#x2013;90. doi: 10.1002/glia.23885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23885</ArticleId><ArticleId IdType="pubmed">32662924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T.-S., Lim H.-K., Lee J.Y., Kim D.-J., Park S., Lee C., Lee C.-U. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer&#x2019;s disease. Neurosci. Lett. 2008;436:196&#x2013;200. doi: 10.1016/j.neulet.2008.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.03.019</ArticleId><ArticleId IdType="pubmed">18378084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulczy&#x144;ska-Przybik A., S&#x142;owik A., Mroczko P., Borawski B., Groblewska M., Borawska R., Mroczko B. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia. Curr. Alzheimer Res. 2020;17:709&#x2013;721. doi: 10.2174/1567205017666201109095657.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205017666201109095657</ArticleId><ArticleId IdType="pubmed">33167838</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011;69:570&#x2013;580. doi: 10.1002/ana.22311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22311</ArticleId><ArticleId IdType="pmc">PMC3117674</ArticleId><ArticleId IdType="pubmed">21400565</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A., Garc&#xed;a-Garc&#xed;a E., Straccia M., Comella-Bolla A., Miguez A., Masana M., Alberch J., Canals J.M., Rodr&#xed;guez M.J. Reduced Fractalkine Levels Lead to Striatal Synaptic Plasticity Deficits in Huntington&#x2019;s Disease. Front. Cell. Neurosci. 2020;14:163. doi: 10.3389/fncel.2020.00163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00163</ArticleId><ArticleId IdType="pmc">PMC7314984</ArticleId><ArticleId IdType="pubmed">32625064</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Liu Y., Liu X., Li S., Cheng C., Chen S., Le W. Dynamic changes of CX3CL1/CX3CR1 axis during microglial activation and motor neuron loss in the spinal cord of ALS mouse model. Transl. Neurodegener. 2018;7:1&#x2013;14. doi: 10.1186/s40035-018-0138-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-018-0138-4</ArticleId><ArticleId IdType="pmc">PMC6309063</ArticleId><ArticleId IdType="pubmed">30607245</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabon M.M., Bachstetter A.D., Hudson C.E., Gemma C., Bickford P.C. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson&#x2019;s disease. J. Neuroinflamm. 2011;8:1&#x2013;7. doi: 10.1186/1742-2094-8-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-9</ArticleId><ArticleId IdType="pmc">PMC3039584</ArticleId><ArticleId IdType="pubmed">21266082</ArticleId></ArticleIdList></Reference><Reference><Citation>Morganti J.M., Nash K.R., Grimmig B.A., Ranjit S., Small B., Bickford P.C., Gemma C. The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson&#x2019;s disease. J. Neurosci. 2012;32:14592&#x2013;14601. doi: 10.1523/JNEUROSCI.0539-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0539-12.2012</ArticleId><ArticleId IdType="pmc">PMC3501652</ArticleId><ArticleId IdType="pubmed">23077045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash K.R., Lee D.C., Hunt J.B., Jr., Morganti J.M., Selenica M.-L., Moran P., Reid P., Brownlow M., Yang C.G.-Y., Savalia M., et al. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol. Aging. 2013;34:1540&#x2013;1548. doi: 10.1016/j.neurobiolaging.2012.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.011</ArticleId><ArticleId IdType="pubmed">23332170</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash K.R., Moran P., Finneran D.J., Hudson C., Robinson J., Morgan D., Bickford P.C. Fractalkine over expression suppresses &#x3b1;-synuclein-mediated neurodegeneration. Mol. Ther. 2015;23:17&#x2013;23. doi: 10.1038/mt.2014.175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.175</ArticleId><ArticleId IdType="pmc">PMC4426798</ArticleId><ArticleId IdType="pubmed">25195598</ArticleId></ArticleIdList></Reference><Reference><Citation>Merino J.J., Mu&#xf1;et&#xf3;n-G&#xf3;mez V., Alv&#xe1;rez M.-I., Toledano-D&#xed;az A. Effects of cx3cr1 and fractalkine chemokines in amyloid &#x3b2; clearance and p-tau accumulation in Alzheimer, s disease (ad) rodent models: Is fractalkine a systemic biomarker for ad? Curr. Alzheimer Res. 2016;13:403&#x2013;412. doi: 10.2174/1567205013666151116125714.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666151116125714</ArticleId><ArticleId IdType="pubmed">26567742</ArticleId></ArticleIdList></Reference><Reference><Citation>Finneran D.J., Morgan D., Gordon M.N., Nash K.R. CNS-Wide over expression of fractalkine improves cognitive functioning in a tauopathy model. J. Neuroimmune Pharmacol. 2019;14:312&#x2013;325. doi: 10.1007/s11481-018-9822-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-018-9822-5</ArticleId><ArticleId IdType="pmc">PMC6525127</ArticleId><ArticleId IdType="pubmed">30499006</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A., Zhao J., Fan C., Zhu L., Huang C., Li Q., Gan D., Wen C., Chen M., Lu D. Delivery of exogenous proteins by mesenchymal stem cells attenuates early memory deficits in a murine model of Alzheimer&#x2019;s disease. Neurobiol. Aging. 2020;86:81&#x2013;91. doi: 10.1016/j.neurobiolaging.2019.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.10.012</ArticleId><ArticleId IdType="pubmed">31837910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Varvel N.H., Konerth M.E., Xu G., Cardona A.E., Ransohoff R.M., Lamb B.T. CX3CR1 deficiency alters microglial activation and reduces &#x3b2;-amyloid deposition in two Alzheimer&#x2019;s disease mouse models. Am. J. Pathol. 2010;177:2549&#x2013;2562. doi: 10.2353/ajpath.2010.100265.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2010.100265</ArticleId><ArticleId IdType="pmc">PMC2966811</ArticleId><ArticleId IdType="pubmed">20864679</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan S., Hong-Min T., Yi F., Jun-Peng G., Yue F., Yan-Hong T., Yun-Ke Y., Wen-Wei L., Xiang-Yu W., Jun M., et al. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson&#x2019;s disease. Neurobiol. Aging. 2011;32:443&#x2013;458. doi: 10.1016/j.neurobiolaging.2009.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.03.004</ArticleId><ArticleId IdType="pubmed">19368990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Bie B., Yang H., Xu J.J., Brown D.L., Naguib M. Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency. Neurobiol. Aging. 2013;34:2843&#x2013;2852. doi: 10.1016/j.neurobiolaging.2013.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.06.003</ArticleId><ArticleId IdType="pubmed">23855980</ArticleId></ArticleIdList></Reference><Reference><Citation>Dworzak J., Renvois&#xe9; B., Habchi J., Yates E.V., Combadi&#xe8;re C., Knowles T.P., Dobson C.M., Blackstone C., Paulsen O., Murphy P.M. Neuronal Cx3cr1 deficiency protects against amyloid &#x3b2;-induced neurotoxicity. PLoS ONE. 2015;10:e0127730. doi: 10.1371/journal.pone.0127730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127730</ArticleId><ArticleId IdType="pmc">PMC4454597</ArticleId><ArticleId IdType="pubmed">26038823</ArticleId></ArticleIdList></Reference><Reference><Citation>Thome A.D., Standaert D.G., Harms A.S. Fractalkine signaling regulates the inflammatory response in an &#x3b1;-synuclein model of Parkinson disease. PLoS ONE. 2015;10:e0140566. doi: 10.1371/journal.pone.0140566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0140566</ArticleId><ArticleId IdType="pmc">PMC4607155</ArticleId><ArticleId IdType="pubmed">26469270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S.E., Allison E.K., Coleman U., Kingery-Gallagher N.D., El Khoury J. Heterozygous CX3CR1 deficiency in microglia restores neuronal &#x3b2;-Amyloid clearance pathways and slows progression of Alzheimer&#x2019;s Like-Disease in PS1-APP Mice. Front. Immunol. 2019;10:2780. doi: 10.3389/fimmu.2019.02780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02780</ArticleId><ArticleId IdType="pmc">PMC6900980</ArticleId><ArticleId IdType="pubmed">31849963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I., Innamorato N.G., Jaworski T., Rabano A., K&#xfc;gler S., Van Leuven F., Cuadrado A. Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain. 2014;137:78&#x2013;91. doi: 10.1093/brain/awt323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt323</ArticleId><ArticleId IdType="pubmed">24277722</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s M., Llorens-Mart&#xed;n M., Perea J.R., Jurado-Arjona J., R&#xe1;bano A., Hern&#xe1;ndez F., Avila J. Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol. Neurodegener. 2017;12:1&#x2013;14. doi: 10.1186/s13024-017-0200-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0200-1</ArticleId><ArticleId IdType="pmc">PMC5558740</ArticleId><ArticleId IdType="pubmed">28810892</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-S&#xe1;nchez S., Garc&#xed;a-Yag&#xfc;e &#xc1;.J., L&#xf3;pez-Royo T., Casarejos M., Lanciego J.L., Lastres-Becker I. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson&#x2019;s disease. Glia. 2018;66:1752&#x2013;1762. doi: 10.1002/glia.23338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23338</ArticleId><ArticleId IdType="pubmed">29624735</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Hong K., Chen H., Niu Y., Duan W., Liu Y., Ji Y., Deng B., Li Y., Li Z., et al. Evidence for a protective role of the CX3CL1/CX3CR1 axis in a model of amyotrophic lateral sclerosis. Biol. Chem. 2019;400:651&#x2013;661. doi: 10.1515/hsz-2018-0204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2018-0204</ArticleId><ArticleId IdType="pubmed">30352020</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo E., McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature. 1990;347:762&#x2013;765. doi: 10.1038/347762a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/347762a0</ArticleId><ArticleId IdType="pubmed">2172829</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen E.C., Johnson E.C., Wagner H., Tseng H.M., Sung L.A., Wagner P.D. Angiogenic growth factor mRNA responses in muscle to a single bout of exercise. J. Appl. Physiol. 1996;81:355&#x2013;361. doi: 10.1152/jappl.1996.81.1.355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1996.81.1.355</ArticleId><ArticleId IdType="pubmed">8828685</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow N.G., Kraus W.E., Moore J.W., Williams R.S., Swain J.L. Increased expression of fibroblast growth factors in a rabbit skeletal muscle model of exercise conditioning. J. Clin. Investig. 1990;85:1816&#x2013;1820. doi: 10.1172/JCI114640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI114640</ArticleId><ArticleId IdType="pmc">PMC296645</ArticleId><ArticleId IdType="pubmed">2347914</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Pinilla F., Dao L., So V. Physical exercise induces FGF-2 and its mRNA in the hippocampus. Brain Res. 1997;764:1&#x2013;8. doi: 10.1016/S0006-8993(97)00375-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(97)00375-2</ArticleId><ArticleId IdType="pubmed">9295187</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D.R., Ruan Y., Adams S.C., Courneya K.S., Friedenreich C.M. The impact of exercise on growth factors (VEGF and FGF2): Results from a 12-month randomized intervention trial. Eur. Rev. Aging Phys. Act. 2019;16:1&#x2013;6. doi: 10.1186/s11556-019-0215-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11556-019-0215-4</ArticleId><ArticleId IdType="pmc">PMC6589878</ArticleId><ArticleId IdType="pubmed">31285780</ArticleId></ArticleIdList></Reference><Reference><Citation>Temmerman K., Ebert A.D., M&#xfc;ller H.-M., Sinning I., Tews I., Nickel W. A direct role for phosphatidylinositol-4, 5-bisphosphate in unconventional secretion of fibroblast growth factor 2. Traffic. 2008;9:1204&#x2013;1217. doi: 10.1111/j.1600-0854.2008.00749.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2008.00749.x</ArticleId><ArticleId IdType="pubmed">18419755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zehe C., Engling A., Wegehingel S., Sch&#xe4;fer T., Nickel W. Cell-Surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2. Proc. Natl. Acad. Sci. USA. 2006;103:15479&#x2013;15484. doi: 10.1073/pnas.0605997103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605997103</ArticleId><ArticleId IdType="pmc">PMC1622848</ArticleId><ArticleId IdType="pubmed">17030799</ArticleId></ArticleIdList></Reference><Reference><Citation>Steringer J.P., Bleicken S., Andreas H., Zacherl S., Laussmann M., Temmerman K., Contreras F.X., Bharat T.A.M., Lechner J., M&#xfc;ller H.-M., et al. Phosphatidylinositol 4, 5-bisphosphate (PI (4, 5) P2)-dependent oligomerization of fibroblast growth factor 2 (FGF2) triggers the formation of a lipidic membrane pore implicated in unconventional secretion. J. Biol. Chem. 2012;287:27659&#x2013;27669. doi: 10.1074/jbc.M112.381939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.381939</ArticleId><ArticleId IdType="pmc">PMC3431657</ArticleId><ArticleId IdType="pubmed">22730382</ArticleId></ArticleIdList></Reference><Reference><Citation>Steringer J.P., Lange S., &#x10c;ujov&#xe1; S., &#x160;achl R., Poojari C., Lolicato F., Beutel O., M&#xfc;ller H.-M., Unger S., Coskun &#xdc;., et al. Key steps in unconventional secretion of fibroblast growth factor 2 reconstituted with purified components. eLife. 2017;6:e28985. doi: 10.7554/eLife.28985.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.28985</ArticleId><ArticleId IdType="pmc">PMC5601999</ArticleId><ArticleId IdType="pubmed">28722655</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian X., Davis A.A., Goderie S.K., Temple S. FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron. 1997;18:81&#x2013;93. doi: 10.1016/S0896-6273(01)80048-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)80048-9</ArticleId><ArticleId IdType="pubmed">9010207</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccarino F.M., Schwartz M.L., Raballo R., Nilsen J., Rhee J., Zhou M., Doetschman T., Coffin J.D., Wyland J.J., Hung Y.-T.E. Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat. Neurosci. 1999;2:246&#x2013;253. doi: 10.1038/6350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/6350</ArticleId><ArticleId IdType="pubmed">10195217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura S., Takagi Y., Harada J., Teramoto T., Thomas S.S., Waeber C., Bakowska J.C., Breakefield X.O., Moskowitz M.A. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proc. Natl. Acad. Sci. USA. 2001;98:5874&#x2013;5879. doi: 10.1073/pnas.101034998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.101034998</ArticleId><ArticleId IdType="pmc">PMC33306</ArticleId><ArticleId IdType="pubmed">11320217</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K., Sun Y., Xie L., Batteur S., Mao X.O., Smelick C., Logvinova A., Greenberg D.A. Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell. 2003;2:175&#x2013;183. doi: 10.1046/j.1474-9728.2003.00046.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1474-9728.2003.00046.x</ArticleId><ArticleId IdType="pubmed">12882410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mud&#xf2; G., Bonomo A., Di Liberto V., Frinchi M., Fuxe K., Belluardo N. The FGF-2/FGFRs neurotrophic system promotes neurogenesis in the adult brain. J. Neural Transm. 2009;116:995&#x2013;1005. doi: 10.1007/s00702-009-0207-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-009-0207-z</ArticleId><ArticleId IdType="pubmed">19291360</ArticleId></ArticleIdList></Reference><Reference><Citation>Presta M., Andr&#xe9;s G., Leali D., Dell&#x2019;Era P., Ronca R. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur. Cytokine Netw. 2009;20:39&#x2013;50. doi: 10.1684/ecn.2009.0155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/ecn.2009.0155</ArticleId><ArticleId IdType="pubmed">19541589</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M., Kakkar A., Sharma R., Kharbanda O.P., Monga N., Kumar M., Chowdhary S., Airan B., Mohanty S. Synergistic effect of BDNF and FGF2 in efficient generation of functional dopaminergic neurons from human mesenchymal stem cells. Sci. Rep. 2017;7:1&#x2013;13. doi: 10.1038/s41598-017-11028-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-11028-z</ArticleId><ArticleId IdType="pmc">PMC5583182</ArticleId><ArticleId IdType="pubmed">28871128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K., LaFevre-Bernt M., Sun Y., Chen S., Gafni J., Crippen D., Logvinova A., Ross C.A., Greenberg D.A., Ellerby L.M. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2005;102:18189&#x2013;18194. doi: 10.1073/pnas.0506375102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506375102</ArticleId><ArticleId IdType="pmc">PMC1312383</ArticleId><ArticleId IdType="pubmed">16326808</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J., Xie L., Jin K., Greenberg D.A., Andersen J.K. Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson&#x2019;s disease. Neuroscience. 2008;153:664&#x2013;670. doi: 10.1016/j.neuroscience.2008.02.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.02.063</ArticleId><ArticleId IdType="pmc">PMC2864598</ArticleId><ArticleId IdType="pubmed">18407421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota T., Ingraham K.L., Jacobsen M.T., Xiong H., Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer&#x2019;s disease and has therapeutic implications for neurocognitive disorders. Proc. Natl. Acad. Sci. USA. 2011;108:E1339&#x2013;E1348. doi: 10.1073/pnas.1102349108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1102349108</ArticleId><ArticleId IdType="pmc">PMC3241747</ArticleId><ArticleId IdType="pubmed">22042871</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H., Xiao Z., Huang J. C6 glioma-secreted NGF and FGF2 regulate neuronal APP processing through up-regulation of ADAM10 and down-regulation of BACE1, respectively. J. Mol. Neurosci. 2016;59:334&#x2013;342. doi: 10.1007/s12031-015-0690-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-015-0690-7</ArticleId><ArticleId IdType="pubmed">26614345</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopa E.G., Gonzalez A.-M., Chorsky R., Corona R.J., Alvarez J., Bird E.D., Baird A. Basic fibroblast growth factor in Alzheimer&#x2019;s disease. Biochem. Biophys. Res. Commun. 1990;171:690&#x2013;696. doi: 10.1016/0006-291X(90)91201-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(90)91201-3</ArticleId><ArticleId IdType="pubmed">2403357</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings B.J., Su J.H., Cotman C.W. Neuritic involvement within bFGF immunopositive plaques of Alzheimer&#x2019;s disease. Exp. Neurol. 1993;124:315&#x2013;325. doi: 10.1006/exnr.1993.1202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1993.1202</ArticleId><ArticleId IdType="pubmed">8287930</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson A., Larsson A., Nygren I., Blennow K., Askmark H. Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis. Neuroreport. 2003;14:1867&#x2013;1869. doi: 10.1097/00001756-200310060-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200310060-00022</ArticleId><ArticleId IdType="pubmed">14534437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y., Iqbal K., Grundke-Iqbal I. Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. J. Neurosci. 1999;19:5245&#x2013;5254. doi: 10.1523/JNEUROSCI.19-13-05245.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.19-13-05245.1999</ArticleId><ArticleId IdType="pmc">PMC6782310</ArticleId><ArticleId IdType="pubmed">10377336</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Tung Y.-C., Li B., Iqbal K., Grundke-Iqbal I. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol. Aging. 2007;28:1148&#x2013;1162. doi: 10.1016/j.neurobiolaging.2006.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.05.036</ArticleId><ArticleId IdType="pubmed">16859812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y., Lee M.H., Li L., Iqbal K., Grundke-Iqbal I. The dentate gyrus neurogenesis: A therapeutic target for Alzheimer&#x2019;s disease. Acta Neuropathol. 2003;105:225&#x2013;232. doi: 10.1007/s00401-002-0636-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-002-0636-3</ArticleId><ArticleId IdType="pubmed">12557008</ArticleId></ArticleIdList></Reference><Reference><Citation>Thau N., Jungnickel J., Knippenberg S., Ratzka A., Dengler R., Petri S., Grothe C. Prolonged survival and milder impairment of motor function in the SOD1 ALS mouse model devoid of fibroblast growth factor 2. Neurobiol. Dis. 2012;47:248&#x2013;257. doi: 10.1016/j.nbd.2012.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.04.008</ArticleId><ArticleId IdType="pubmed">22542539</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta. 2000;1492:203&#x2013;206. doi: 10.1016/S0167-4781(00)00067-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-4781(00)00067-1</ArticleId><ArticleId IdType="pubmed">10858549</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher F.M., Maratos-Flier E. Understanding the physiology of FGF21. Annu. Rev. Physiol. 2016;78:223&#x2013;241. doi: 10.1146/annurev-physiol-021115-105339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-021115-105339</ArticleId><ArticleId IdType="pubmed">26654352</ArticleId></ArticleIdList></Reference><Reference><Citation>Tezze C., Romanello V., Sandri M. FGF21 as Modulator of Metabolism in Health and Disease. Front. Physiol. 2019;10:419. doi: 10.3389/fphys.2019.00419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.00419</ArticleId><ArticleId IdType="pmc">PMC6478891</ArticleId><ArticleId IdType="pubmed">31057418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J.E., Ebling F.J.P., Samms R.J., Tsintzas K. Going back to the biology of FGF21: New insights. Trends Endocrinol. Metab. 2019;30:491&#x2013;504. doi: 10.1016/j.tem.2019.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2019.05.007</ArticleId><ArticleId IdType="pubmed">31248786</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuevas-Ramos D., Almeda-Vald&#xe9;s P., Meza-Arana C.E., Brito-C&#xf3;rdova G., G&#xf3;mez-P&#xe9;rez F.J., Mehta R., Oseguera-Moguel J., Aguilar-Salinas C.A. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS ONE. 2012;7:e38022. doi: 10.1371/journal.pone.0038022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0038022</ArticleId><ArticleId IdType="pmc">PMC3365112</ArticleId><ArticleId IdType="pubmed">22701542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.H., Kim S.H., Min Y.-K., Yang H.-M., Lee J.-B., Lee M.-S. Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS ONE. 2013;8:e63517. doi: 10.1371/journal.pone.0063517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0063517</ArticleId><ArticleId IdType="pmc">PMC3646740</ArticleId><ArticleId IdType="pubmed">23667629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen J.S., Clemmesen J.O., Secher N.H., Hoene M., Drescher A., Weigert C., Pedersen B.K., Plomgaard P. Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans. Mol. Metab. 2015;4:551&#x2013;560. doi: 10.1016/j.molmet.2015.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2015.06.001</ArticleId><ArticleId IdType="pmc">PMC4529499</ArticleId><ArticleId IdType="pubmed">26266087</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng L., Liao B., Jin L., Huang Z., Triggle C.R., Ding H., Zhang J., Huang Y., Lin Z., Xu A. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep. 2019;26:2738&#x2013;2752.e4. doi: 10.1016/j.celrep.2019.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.02.014</ArticleId><ArticleId IdType="pubmed">30840894</ArticleId></ArticleIdList></Reference><Reference><Citation>Douris N., Stevanovic D.M., Fisher F.M., Cisu T.I., Chee M.J., Nguyen N.L., Zarebidaki E., Adams A.C., Kharitonenkov A., Flier J.S., et al. Bart Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology. 2015;156:2470&#x2013;2481. doi: 10.1210/en.2014-2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2014-2001</ArticleId><ArticleId IdType="pmc">PMC4475718</ArticleId><ArticleId IdType="pubmed">25924103</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumiya Y., Bina H.A., Ouchi N., Akasaki Y., Kharitonenkov A., Walsh K. FGF21 is an Akt-regulated myokine. FEBS Lett. 2008;582:3805&#x2013;3810. doi: 10.1016/j.febslet.2008.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.10.021</ArticleId><ArticleId IdType="pmc">PMC2604129</ArticleId><ArticleId IdType="pubmed">18948104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanimura Y., Aoi W., Takanami Y., Kawai Y., Mizushima K., Naito Y., Yoshikawa T. Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation. Physiol. Rep. 2016;4:e12828. doi: 10.14814/phy2.12828.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.12828</ArticleId><ArticleId IdType="pmc">PMC4923231</ArticleId><ArticleId IdType="pubmed">27335433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.H., Jeong Y.T., Oh H., Kim S.H., Cho J.M., Kim Y.-N., Kim S.S., Kim D.H., Hur K.Y., Kim H.K., et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 2013;19:83. doi: 10.1038/nm.3014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3014</ArticleId><ArticleId IdType="pubmed">23202295</ArticleId></ArticleIdList></Reference><Reference><Citation>Keipert S., Ost M., Johann K., Imber F., Jastroch M., van Schothorst E.M., Keijer J., Klaus S. Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. Am. J. Physiol. Endocrinol. Metab. 2014;306:E469&#x2013;E482. doi: 10.1152/ajpendo.00330.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00330.2013</ArticleId><ArticleId IdType="pubmed">24347058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji K., Zheng J., Lv J., Xu J., Ji X., Luo Y.-B., Li W., Zhao Y., Yan C. Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1&#x3b1; pathway. Free Radic. Biol. Med. 2015;84:161&#x2013;170. doi: 10.1016/j.freeradbiomed.2015.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.03.020</ArticleId><ArticleId IdType="pubmed">25843656</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira R.O., Tadinada S.M., Zasadny F.M., Oliveira K.J., Pires K.M.P., Olvera A., Jeffers J., Souvenir R., Mcglauflin R., Seei A., et al. OPA 1 deficiency promotes secretion of FGF 21 from muscle that prevents obesity and insulin resistance. EMBO J. 2017;36:2126&#x2013;2145. doi: 10.15252/embj.201696179.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201696179</ArticleId><ArticleId IdType="pmc">PMC5510002</ArticleId><ArticleId IdType="pubmed">28607005</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery M.K., Mokhtar R., Bayliss J., Parkington H.C., Suturin V.M., Bruce C.R., Watt M.J. Perilipin 5 deletion unmasks an endoplasmic reticulum stress-fibroblast growth factor 21 axis in skeletal muscle. Diabetes. 2018;67:594&#x2013;606. doi: 10.2337/db17-0923.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db17-0923</ArticleId><ArticleId IdType="pubmed">29378767</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsuchou H., Pan W., Kastin A.J. The fasting polypeptide FGF21 can enter brain from blood. Peptides. 2007;28:2382&#x2013;2386. doi: 10.1016/j.peptides.2007.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2007.10.007</ArticleId><ArticleId IdType="pmc">PMC2151924</ArticleId><ArticleId IdType="pubmed">17996984</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa-Nguanmoo P., Tanajak P., Kerdphoo S., Satjaritanun P., Wang X., Liang G., Li X., Jiang C., Pratchayasakul W., Chattipakorn N., et al. FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats. Horm. Behav. 2016;85:86&#x2013;95. doi: 10.1016/j.yhbeh.2016.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yhbeh.2016.08.006</ArticleId><ArticleId IdType="pubmed">27566237</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa-Nguanmoo P., Tanajak P., Kerdphoo S., Jaiwongkam T., Wang X., Liang G., Li X., Jiang C., Pratchayasakul W., Chattipakorn N., et al. FGF21 and DPP-4 inhibitor equally prevents cognitive decline in obese rats. Biomed. Pharmacother. 2018;97:1663&#x2013;1672. doi: 10.1016/j.biopha.2017.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.12.021</ArticleId><ArticleId IdType="pubmed">29793329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Yuan J., Yu Z., Lin L., Jiang Y., Cao Z., Zhuang P., Whalen M.J., Song B., Wang X.-J., et al. FGF21 attenuates high-fat diet-induced cognitive impairment via metabolic regulation and anti-inflammation of obese mice. Mol. Neurobiol. 2018;55:4702&#x2013;4717. doi: 10.1007/s12035-017-0663-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0663-7</ArticleId><ArticleId IdType="pmc">PMC5971086</ArticleId><ArticleId IdType="pubmed">28712011</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahror R.A., Linares G.R., Wang Y., Hsueh S.-C., Wu C.-C., Chuang D.-M., Chiang Y.-H., Chen K.-Y. Transplantation of mesenchymal stem cells overexpressing fibroblast growth factor 21 facilitates cognitive recovery and enhances neurogenesis in a mouse model of traumatic brain injury. J. Neurotrauma. 2020;37:14&#x2013;26. doi: 10.1089/neu.2019.6422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2019.6422</ArticleId><ArticleId IdType="pmc">PMC6921331</ArticleId><ArticleId IdType="pubmed">31298621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Hu J., Liu H., Xiong Y., Zou Y., Huang W., Shao M., Wu J., Yu L., Wang X., et al. FGF21 protects the blood-brain barrier by upregulating PPAR&#x3b3; via FGFR1/&#x3b2;-klotho after traumatic brain injury. J. Neurotrauma. 2018;35:2091&#x2013;2103. doi: 10.1089/neu.2017.5271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2017.5271</ArticleId><ArticleId IdType="pubmed">29648978</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Liu N., Wang Q., Yu Z., Lin L., Yuan J., Guo S., Ahn B.J., Wang X.-J., Li X., et al. Endocrine regulator rFGF21 (recombinant human fibroblast growth factor 21) improves neurological outcomes following focal ischemic stroke of type 2 diabetes mellitus male mice. Stroke. 2018;49:3039&#x2013;3049. doi: 10.1161/STROKEAHA.118.022119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.118.022119</ArticleId><ArticleId IdType="pmc">PMC6310061</ArticleId><ArticleId IdType="pubmed">30571410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Lin L., Liu N., Wang Q., Yuan J., Li Y., Chung K.K., Guo S., Yu Z., Wang X. FGF21 protects against aggravated blood-brain barrier disruption after ischemic focal stroke in diabetic db/db male mice via cerebrovascular PPAR&#x3b3; activation. Int. J. Mol. Sci. 2020;21:824. doi: 10.3390/ijms21030824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030824</ArticleId><ArticleId IdType="pmc">PMC7037567</ArticleId><ArticleId IdType="pubmed">32012810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z., Lin L., Jiang Y., Chin I., Wang X., Li X., Lo E.H., Wang X. Recombinant FGF21 protects against blood-brain barrier leakage through Nrf2 upregulation in type 2 diabetes mice. Mol. Neurobiol. 2019;56:2314&#x2013;2327. doi: 10.1007/s12035-018-1234-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1234-2</ArticleId><ArticleId IdType="pmc">PMC6339597</ArticleId><ArticleId IdType="pubmed">30022432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Liu F., Zhu L., Lin P., Han F., Wang X., Tan X., Lin L., Xiong Y. FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia/macrophages. J. Neuroinflamm. 2020;17:1&#x2013;17. doi: 10.1186/s12974-020-01921-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-020-01921-2</ArticleId><ArticleId IdType="pmc">PMC7457364</ArticleId><ArticleId IdType="pubmed">32867781</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;hlmann C., W&#xf6;lk T., Bl&#xfc;mel T., Stahn L., Vollmar B., Kuhla A. Long-Term caloric restriction in ApoE-deficient mice results in neuroprotection via Fgf21-induced AMPK/mTOR pathway. Aging. 2016;8:2777. doi: 10.18632/aging.101086.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101086</ArticleId><ArticleId IdType="pmc">PMC5191869</ArticleId><ArticleId IdType="pubmed">27902456</ArticleId></ArticleIdList></Reference><Reference><Citation>Amiri M., Braidy N., Aminzadeh M. Protective Effects of Fibroblast Growth Factor 21 against Amyloid-&#x3b2; 1&#x2013;42-Induced Toxicity in SH-SY5Y Cells. Neurotox. Res. 2018;34:574&#x2013;583. doi: 10.1007/s12640-018-9914-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-018-9914-2</ArticleId><ArticleId IdType="pubmed">29869772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Chen S.-T., Sun Y., Xu Z., Wang Y., Yao S.-Y., Yao W.-B., Gao X.-D. Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer&#x2019;s disease. Redox Biol. 2019;22:101133. doi: 10.1016/j.redox.2019.101133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2019.101133</ArticleId><ArticleId IdType="pmc">PMC6383137</ArticleId><ArticleId IdType="pubmed">30785085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Wang Y., Chen S.-T., Chen Y.-J., Shen J., Yao W.-B., Gao X.-D., Chen S. Modulation of the Astrocyte-Neuron Lactate Shuttle System contributes to Neuroprotective action of Fibroblast Growth Factor 21. Theranostics. 2020;10:8430. doi: 10.7150/thno.44370.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.44370</ArticleId><ArticleId IdType="pmc">PMC7381735</ArticleId><ArticleId IdType="pubmed">32724479</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe4;kel&#xe4; J., Tselykh T.V., Maiorana F., Eriksson O., Do H.T., Mud&#xf2; G., Korhonen L.T., Belluardo N., Lindholm D. Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1&#x3b1; in human dopaminergic neurons via Sirtuin-1. SpringerPlus. 2014;3:1&#x2013;12. doi: 10.1186/2193-1801-3-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2193-1801-3-2</ArticleId><ArticleId IdType="pmc">PMC4409609</ArticleId><ArticleId IdType="pubmed">25932355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Shen J., Qi G., Zha Q., Zhang C., Yao W., Gao X., Chen S. Potential therapeutic role of fibroblast growth factor 21 in neurodegeneration: Evidence for ameliorating parkinsonism via silent information regulator 2 homolog 1 and implication for gene therapy. Neuropharmacology. 2020;181:108335. doi: 10.1016/j.neuropharm.2020.108335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.108335</ArticleId><ArticleId IdType="pubmed">32979381</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X., Ma J., Mu D., Li B., Lian B., Sun C. FGF21 Protects Dopaminergic Neurons in Parkinson&#x2019;s Disease Models Via Repression of Neuroinflammation. Neurotox. Res. 2020;37:616&#x2013;627. doi: 10.1007/s12640-019-00151-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-019-00151-6</ArticleId><ArticleId IdType="pubmed">31997152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakoty V., Sarathlal K., Tang R.-D., Yang C.H., Dubey S.K., Taliyan R. Fibroblast growth factor 21 and autophagy: A complex interplay in Parkinson disease. Biomed. Pharmacother. 2020;127:110145. doi: 10.1016/j.biopha.2020.110145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110145</ArticleId><ArticleId IdType="pubmed">32361164</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaye J.B., Lanznaster D., Veyrat-Durebex C., Fontaine A., Bacle G., Lefevre A., Hergesheimer R., Lecron J.C., Vourc&#x2019;h P., Andres C.R., et al. Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model. Neurotherapeutics. 2020:1&#x2013;12. doi: 10.1007/s13311-020-00933-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-020-00933-3</ArticleId><ArticleId IdType="pmc">PMC8116478</ArticleId><ArticleId IdType="pubmed">33021723</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbi S., Quipildor G.F., Barzilai N., Huffman D.M., Milman S. 40 YEARS of IGF1: IGF1: The Jekyll and Hyde of the aging brain. J. Mol. Endocrinol. 2018;61:T171&#x2013;T185. doi: 10.1530/JME-18-0093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-18-0093</ArticleId><ArticleId IdType="pmc">PMC5988994</ArticleId><ArticleId IdType="pubmed">29739805</ArticleId></ArticleIdList></Reference><Reference><Citation>Perdue J.F. Chemistry, structure, and function of insulin-like growth factors and their receptors: A review. Can. J. Biochem. Cell. Biol. 1984;62:1237&#x2013;1245. doi: 10.1139/o84-158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/o84-158</ArticleId><ArticleId IdType="pubmed">6098361</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.D., Rotwein P., Novakofski J., Bechtel P.J. Induction of mRNA for IGF-I and-II during growth hormone-stimulated muscle hypertrophy. Am. J. Physiol. 1988;255:E513&#x2013;E517. doi: 10.1152/ajpendo.1988.255.4.E513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.1988.255.4.E513</ArticleId><ArticleId IdType="pubmed">3177637</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss M.W., Erickson K.I., Prakash R.S., Chaddock L., Kim J.S., Alves H., Szabo A., Phillips S.M., W&#xf3;jcicki T.R., Mailey E.L., et al. Neurobiological markers of exercise-related brain plasticity in older adults. Brain Behav. Immun. 2013;28:90&#x2013;99. doi: 10.1016/j.bbi.2012.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2012.10.021</ArticleId><ArticleId IdType="pmc">PMC3544982</ArticleId><ArticleId IdType="pubmed">23123199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-L., Wang C.-H., Pan C.-Y., Chen F.-C. The effects of long-term resistance exercise on the relationship between neurocognitive performance and GH, IGF-1, and homocysteine levels in the elderly. Front. Behav. Neurosci. 2015;9:23. doi: 10.3389/fnbeh.2015.00023.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2015.00023</ArticleId><ArticleId IdType="pmc">PMC4322723</ArticleId><ArticleId IdType="pubmed">25713518</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.-T., Chung Y.-C., Chen Y.-J., Ho S.-Y., Wu H.-J. Effects of different types of exercise on body composition, muscle strength, and IGF-1 in the elderly with sarcopenic obesity. J. Am. Geriatr. Soc. 2017;65:827&#x2013;832. doi: 10.1111/jgs.14722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14722</ArticleId><ArticleId IdType="pubmed">28205203</ArticleId></ArticleIdList></Reference><Reference><Citation>Trejo J.L., Llorens-Martin M.V., Torres-Alem&#xe1;n I. The effects of exercise on spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent mechanism related to hippocampal neurogenesis. Mol. Cell. Neurosci. 2008;37:402&#x2013;411. doi: 10.1016/j.mcn.2007.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2007.10.016</ArticleId><ArticleId IdType="pubmed">18086533</ArticleId></ArticleIdList></Reference><Reference><Citation>Carro E., Nu&#xf1;ez A., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 2000;20:2926&#x2013;2933. doi: 10.1523/JNEUROSCI.20-08-02926.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-08-02926.2000</ArticleId><ArticleId IdType="pmc">PMC6772191</ArticleId><ArticleId IdType="pubmed">10751445</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kusky J., Ye P. Neurodevelopmental effects of insulin-like growth factor signaling. Front. Neuroendocrinol. 2012;33:230&#x2013;251. doi: 10.1016/j.yfrne.2012.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2012.06.002</ArticleId><ArticleId IdType="pmc">PMC3677055</ArticleId><ArticleId IdType="pubmed">22710100</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Delaimy W.K., Von Muhlen D., Barrett-Connor E. Insulinlike Growth Factor-1, Insulinlike Growth Factor Binding Protein-1, and Cognitive Function in Older Men and Women. J. Am. Geriatr. Soc. 2009;57:1441&#x2013;1446. doi: 10.1111/j.1532-5415.2009.02343.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2009.02343.x</ArticleId><ArticleId IdType="pmc">PMC2728156</ArticleId><ArticleId IdType="pubmed">19515112</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi T., Shimada H., Makizako H., Tsutsumimoto K., Hotta R., Nakakubo S., Suzuki T. Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed. Neurobiol. Aging. 2015;36:942&#x2013;947. doi: 10.1016/j.neurobiolaging.2014.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.035</ArticleId><ArticleId IdType="pubmed">25467636</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumati S., Burger H., Martens S., van der Schouw Y.T., Aleman A. Association between cognition and serum insulin-like growth factor-1 in middle-aged &amp; older men: An 8 year follow-up study. PLoS ONE. 2016;11:e0154450. doi: 10.1371/journal.pone.0154450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154450</ArticleId><ArticleId IdType="pmc">PMC4846160</ArticleId><ArticleId IdType="pubmed">27115487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg A.M.V., Hagen C.E., Machulda M.M., Hollman J.H., Roberts R.O., Knopman D.S., Petersen R.C., Mielke M.M. The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. Neurobiol. Aging. 2018;66:68&#x2013;74. doi: 10.1016/j.neurobiolaging.2017.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.11.017</ArticleId><ArticleId IdType="pmc">PMC5924628</ArticleId><ArticleId IdType="pubmed">29547749</ArticleId></ArticleIdList></Reference><Reference><Citation>Westwood A.J., Beiser A., DeCarli C., Harris T.B., Chen T.C., He X.-M., Roubenoff R., Pikula A., Au R., Braverman L.E., et al. Insulin-Like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014;82:1613&#x2013;1619. doi: 10.1212/WNL.0000000000000382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000382</ArticleId><ArticleId IdType="pmc">PMC4013812</ArticleId><ArticleId IdType="pubmed">24706014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski P.P., Barszczyk A., Forstenpointner J., Zheng W., Feng Z.-P. Meta-Analysis of serum insulin-like growth factor 1 in Alzheimer&#x2019;s disease. PLoS ONE. 2016;11:e0155733. doi: 10.1371/journal.pone.0155733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0155733</ArticleId><ArticleId IdType="pmc">PMC4881955</ArticleId><ArticleId IdType="pubmed">27227831</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilla-Cort&#xe1;zar I., Aguirre G.A., Femat-Rold&#xe1;n G., Mart&#xed;n-Estal I., Espinosa L. Is insulin-like growth factor-1 involved in Parkinson&#x2019;s disease development? J. Transl. Med. 2020;18:70. doi: 10.1186/s12967-020-02223-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02223-0</ArticleId><ArticleId IdType="pmc">PMC7014772</ArticleId><ArticleId IdType="pubmed">32046737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar B.K., Llad&#xf3; J., Sherkat N., Rothstein J.D., Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839&#x2013;842. doi: 10.1126/science.1086137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086137</ArticleId><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Quesada A., Micevych P.E. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res. 2004;75:107&#x2013;116. doi: 10.1002/jnr.10833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10833</ArticleId><ArticleId IdType="pubmed">14689453</ArticleId></ArticleIdList></Reference><Reference><Citation>Quesada A., Lee B.Y., Micevych P.E. PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson&#x2019;s disease. Dev. Neurobiol. 2008;68:632&#x2013;644. doi: 10.1002/dneu.20609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.20609</ArticleId><ArticleId IdType="pmc">PMC2667142</ArticleId><ArticleId IdType="pubmed">18278798</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musar&#xf2; A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert A.D., Beres A.J., Barber A.E., Svendsen C.N. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson&#x2019;s disease. Exp. Neurol. 2008;209:213&#x2013;223. doi: 10.1016/j.expneurol.2007.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.09.022</ArticleId><ArticleId IdType="pubmed">18061591</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte A.I., Petit G.H., Ranganathan S., Li J.-Y., Oliveira C.R., Brundin P., Bj&#xf6;rkqvist M., Rego A.C. IGF-1 protects against diabetic features in an in vivo model of Huntington&#x2019;s disease. Exp. Neurol. 2011;231:314&#x2013;319. doi: 10.1016/j.expneurol.2011.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.06.016</ArticleId><ArticleId IdType="pubmed">21763311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes C., Ribeiro M., Duarte A.I., Humbert S., Saudou F., De Almeida L.P., Hayden M., Rego A.C. IGF-1 intranasal administration rescues Huntington&#x2019;s disease phenotypes in YAC128 mice. Mol. Neurobiol. 2014;49:1126&#x2013;1142. doi: 10.1007/s12035-013-8585-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8585-5</ArticleId><ArticleId IdType="pubmed">24347322</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguado-Llera D., Arilla-Ferreiro E., Campos-Barros A., Puebla-Jim&#xe9;nez L., Barrios V. Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of &#x3b2;-amyloid-treated rats. J. Neurochem. 2005;92:607&#x2013;615. doi: 10.1111/j.1471-4159.2004.02889.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02889.x</ArticleId><ArticleId IdType="pubmed">15659230</ArticleId></ArticleIdList></Reference><Reference><Citation>Carro E., Trejo J.L., Gerber A., Loetscher H., Torrado J., Metzger F., Torres-Aleman I. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging. 2006;27:1250&#x2013;1257. doi: 10.1016/j.neurobiolaging.2005.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.06.015</ArticleId><ArticleId IdType="pubmed">16183170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E., Paulsson J.F., Blinder P., Burstyn-Cohen T., Du D., Estepa G., Adame A., Pham H.M., Holzenberger M., Kelly J.W., et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009;139:1157&#x2013;1169. doi: 10.1016/j.cell.2009.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.11.014</ArticleId><ArticleId IdType="pmc">PMC3017511</ArticleId><ArticleId IdType="pubmed">20005808</ArticleId></ArticleIdList></Reference><Reference><Citation>Freude S., Hettich M.M., Schumann C., St&#xf6;hr O., Koch L., K&#xf6;hler C., Udelhoven M., Leeser U., M&#xfc;ller M., Kubota N., et al. Neuronal IGF-1 resistance reduces A&#x3b2; accumulation and protects against premature death in a model of Alzheimer&#x2019;s disease. FASEB J. 2009;23:3315&#x2013;3324. doi: 10.1096/fj.09-132043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-132043</ArticleId><ArticleId IdType="pubmed">19487308</ArticleId></ArticleIdList></Reference><Reference><Citation>Gontier G., George C., Chaker Z., Holzenberger M., A&#xef;d S. Blocking IGF signaling in adult neurons alleviates Alzheimer&#x2019;s disease pathology through amyloid-&#x3b2; clearance. J. Neurosci. 2015;35:11500&#x2013;11513. doi: 10.1523/JNEUROSCI.0343-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0343-15.2015</ArticleId><ArticleId IdType="pmc">PMC6605240</ArticleId><ArticleId IdType="pubmed">26290229</ArticleId></ArticleIdList></Reference><Reference><Citation>Frater J., Lie D., Bartlett P., McGrath J.J. Insulin-Like Growth Factor 1 (IGF-1) as a marker of cognitive decline in normal ageing: A review. Ageing Res. Rev. 2018;42:14&#x2013;27. doi: 10.1016/j.arr.2017.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2017.12.002</ArticleId><ArticleId IdType="pubmed">29233786</ArticleId></ArticleIdList></Reference><Reference><Citation>Panati K., Suneetha Y., Narala V.R. Irisin/FNDC5&#x2013;An updated review. Eur. Rev. Med. Pharmacol. Sci. 2016;20:689&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">26957272</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin S., Kuloglu T., Aydin S., Kalayci M., Yilmaz M., Cakmak T., Albayrak S., Gungor S., Colakoglu N., Ozercan &#x130;.H. A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides. 2014;61:130&#x2013;136. doi: 10.1016/j.peptides.2014.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2014.09.014</ArticleId><ArticleId IdType="pubmed">25261800</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedrychowski M.P., Wrann C.D., Paulo J.A., Gerber K.K., Szpyt J., Robinson M.M., Nair K.S., Gygi S.P., Spiegelman B.M. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab. 2015;22:734&#x2013;740. doi: 10.1016/j.cmet.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2015.08.001</ArticleId><ArticleId IdType="pmc">PMC4802359</ArticleId><ArticleId IdType="pubmed">26278051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.J., Lee J.O., Kim N., Kim J.K., Kim H.I., Lee Y.W., Kim S.J., Choi J.-I., Oh Y., Kim J.H., et al. Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK. Mol. Endocrinol. 2015;29:873&#x2013;881. doi: 10.1210/me.2014-1353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2014-1353</ArticleId><ArticleId IdType="pmc">PMC5414737</ArticleId><ArticleId IdType="pubmed">25826445</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin C., Liu J., Zhang J., Zhu D., Wang H., Xiong L., Lee Y., Ye J., Lian K., Xu C., et al. Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int. J. Obes. 2016;40:443&#x2013;451. doi: 10.1038/ijo.2015.199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijo.2015.199</ArticleId><ArticleId IdType="pubmed">26403433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H., Wrann C.D., Jedrychowski M., Vidoni S., Kitase Y., Nagano K., Zhou C., Chou J., Parkman V.-J.A., Novick S.J., et al. Irisin mediates effects on bone and fat via &#x3b1;V integrin receptors. Cell. 2018;175:1756&#x2013;1768. doi: 10.1016/j.cell.2018.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.025</ArticleId><ArticleId IdType="pmc">PMC6298040</ArticleId><ArticleId IdType="pubmed">30550785</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon H.-S., Dincer F., Mantzoros C.S. Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism. 2013;62:1131&#x2013;1136. doi: 10.1016/j.metabol.2013.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2013.04.007</ArticleId><ArticleId IdType="pmc">PMC4370428</ArticleId><ArticleId IdType="pubmed">23664146</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrann C.D., White J.P., Salogiannnis J., Laznik-Bogoslavski D., Wu J., Ma D., Lin J.D., Greenberg M.E., Spiegelman B.M. Exercise induces hippocampal BDNF through a PGC-1&#x3b1;/FNDC5 pathway. Cell Metab. 2013;18:649&#x2013;659. doi: 10.1016/j.cmet.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.09.008</ArticleId><ArticleId IdType="pmc">PMC3980968</ArticleId><ArticleId IdType="pubmed">24120943</ArticleId></ArticleIdList></Reference><Reference><Citation>Natalicchio A., Marrano N., Biondi G., Dipaola L., Spagnuolo R., Cignarelli A., Perrini S., Laviola L., Giorgino F. Irisin increases the expression of anorexigenic and neurotrophic genes in mouse brain. Diabetes Metab. Res. Rev. 2020;36:e3238. doi: 10.1002/dmrr.3238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3238</ArticleId><ArticleId IdType="pubmed">31742872</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourenco M.V., Frozza R.L., de Freitas G.B., Zhang H., Kincheski G.C., Ribeiro F.C., Gon&#xe7;alves R.A., Clarke J.R., Beckman D., Staniszewski A., et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer&#x2019;s models. Nat. Med. 2019;25:165&#x2013;175. doi: 10.1038/s41591-018-0275-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0275-4</ArticleId><ArticleId IdType="pmc">PMC6327967</ArticleId><ArticleId IdType="pubmed">30617325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbakhsh S., Safari M., Aldaghi M.R., Sameni H.R., Ghahari L., Lagmouj Y.K., Jaberi K.R., Parsaie H. Irisin protects the substantia nigra dopaminergic neurons in the rat model of Parkinson&#x2019;s disease. Iran. J. Basic Med. Sci. 2019;22:722. doi: 10.22038/ijbms.2019.33444.7987.</Citation><ArticleIdList><ArticleId IdType="doi">10.22038/ijbms.2019.33444.7987</ArticleId><ArticleId IdType="pmc">PMC7196356</ArticleId><ArticleId IdType="pubmed">32373292</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourenco M.V., Ribeiro F.C., Sudo F.K., Drummond C., Assun&#xe7;&#xe3;o N., Vanderborght B., Tovar-Moll F., Mattos P., De Felice F.G., Ferreira S.T. Cerebrospinal fluid irisin correlates with amyloid-&#x3b2;, BDNF, and cognition in Alzheimer&#x2019;s disease. Alzheimers Dement. 2020;12:e12034. doi: 10.1002/dad2.12034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12034</ArticleId><ArticleId IdType="pmc">PMC7306518</ArticleId><ArticleId IdType="pubmed">32582833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Tremolizzo L., Ruscica M., Macchi C., Riva N., Weydt P., Corradi E., Magni P., Sansone V. Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. J. Neurol. 2018;265:3001&#x2013;3008. doi: 10.1007/s00415-018-9093-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9093-3</ArticleId><ArticleId IdType="pubmed">30350169</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicola N.A., Babon J.J. Leukemia inhibitory factor (LIF) Cytokine Growth Factor Rev. 2015;26:533&#x2013;544. doi: 10.1016/j.cytogfr.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4581962</ArticleId><ArticleId IdType="pubmed">26187859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gearing D.P., Gough N.M., King J.A., Hilton D.J., Nicola N.A., Simpson R.J., Nice E.C., Kelso A., Metcalf D. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF) EMBO J. 1987;6:3995&#x2013;4002. doi: 10.1002/j.1460-2075.1987.tb02742.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1987.tb02742.x</ArticleId><ArticleId IdType="pmc">PMC553879</ArticleId><ArticleId IdType="pubmed">3127201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton D.J. LIF: Lots of interesting functions. Trends Biochem. Sci. 1992;17:72&#x2013;76. doi: 10.1016/0968-0004(92)90505-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0968-0004(92)90505-4</ArticleId><ArticleId IdType="pubmed">1566332</ArticleId></ArticleIdList></Reference><Reference><Citation>Broholm C., Mortensen O.H., Nielsen S., Akerstrom T., Zankari A., Dahl B., Pedersen B.K. Exercise induces expression of leukaemia inhibitory factor in human skeletal muscle. J. Physiol. 2008;586:2195&#x2013;2201. doi: 10.1113/jphysiol.2007.149781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2007.149781</ArticleId><ArticleId IdType="pmc">PMC2465206</ArticleId><ArticleId IdType="pubmed">18292129</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia D., Cai M., Xi Y., Du S., ZhenjunTian Interval exercise training increases LIF expression and prevents myocardial infarction-induced skeletal muscle atrophy in rats. Life Sci. 2018;193:77&#x2013;86. doi: 10.1016/j.lfs.2017.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2017.12.009</ArticleId><ArticleId IdType="pubmed">29223542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill E.J., Vernallis A.B. Polarized secretion of leukemia inhibitory factor. BMC Cell Biol. 2008;9:1&#x2013;10. doi: 10.1186/1471-2121-9-53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2121-9-53</ArticleId><ArticleId IdType="pmc">PMC2556326</ArticleId><ArticleId IdType="pubmed">18801170</ArticleId></ArticleIdList></Reference><Reference><Citation>Broholm C., Pedersen B.K. Leukaemia inhibitory factor-an exercise-induced myokine. Exerc. Immunol. Rev. 2010;16:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">20839492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapilevich L.V., Zakharova A.N., Kabachkova A.V., Kironenko T.A., Orlov S.N. Dynamic and static exercises differentially affect plasma cytokine content in elite endurance-and strength-trained athletes and untrained volunteers. Front. Physiol. 2017;8:35. doi: 10.3389/fphys.2017.00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00035</ArticleId><ArticleId IdType="pmc">PMC5276859</ArticleId><ArticleId IdType="pubmed">28194116</ArticleId></ArticleIdList></Reference><Reference><Citation>Broholm C., Laye M.J., Brandt C., Vadalasetty R., Pilegaard H., Pedersen B.K., Scheele C. LIF is a contraction-induced myokine stimulating human myocyte proliferation. J. Appl. Physiol. 2011;111:251&#x2013;259. doi: 10.1152/japplphysiol.01399.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.01399.2010</ArticleId><ArticleId IdType="pubmed">21527666</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W., Kastin A.J., Brennan J.M. Saturable entry of leukemia inhibitory factor from blood to the central nervous system. J. Neuroimmunol. 2000;106:172&#x2013;180. doi: 10.1016/S0165-5728(00)00241-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(00)00241-1</ArticleId><ArticleId IdType="pubmed">10814795</ArticleId></ArticleIdList></Reference><Reference><Citation>Soilu-H&#xe4;nninen M., Broberg E., R&#xf6;ytt&#xe4; M., Mattila P., Rinne J., Hukkanen V. Expression of LIF and LIF receptor beta in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Acta Neurol. Scand. 2010;121:44&#x2013;50. doi: 10.1111/j.1600-0404.2009.01179.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2009.01179.x</ArticleId><ArticleId IdType="pubmed">20074285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Imai T., Shimizu N., Nakagawa H., Ono S. Expression of leukaemia inhibitory factor in skin of patients with amyotrophic lateral sclerosis. Lancet. 1999;353:2126&#x2013;2127. doi: 10.1016/S0140-6736(99)01520-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(99)01520-2</ArticleId><ArticleId IdType="pubmed">10382701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.J., Lee J.O., Lee Y.W., Kim S.A., Seo I.H., Han J.A., Kang M.J., Kim S.J., Cho Y.-H., Park J.-J., et al. Lif, a novel myokine, protects against amyloid-&#x3b2;-induced neurotoxicity via Akt-mediated autophagy signaling in hippocampal cells. Int. J. Neuropsychopharmacol. 2019;22:402&#x2013;414. doi: 10.1093/ijnp/pyz016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyz016</ArticleId><ArticleId IdType="pmc">PMC6545540</ArticleId><ArticleId IdType="pubmed">31125414</ArticleId></ArticleIdList></Reference><Reference><Citation>Feeney S.J., Austin L., Bennett T.M., Kurek J.B., Jean-Francois M.J.B., Muldoon C., Byrne E. The effect of leukaemia inhibitory factor on SOD1 G93A murine amyotrophic lateral sclerosis. Cytokine. 2003;23:108&#x2013;118. doi: 10.1016/S1043-4666(03)00217-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1043-4666(03)00217-5</ArticleId><ArticleId IdType="pubmed">12967646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 2000;1:120&#x2013;130. doi: 10.1038/35040009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35040009</ArticleId><ArticleId IdType="pubmed">11253364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Yankner B.A. Apoptosis in the nervous system. Nature. 2000;407:802&#x2013;809. doi: 10.1038/35037739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35037739</ArticleId><ArticleId IdType="pubmed">11048732</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed J.C. Mechanisms of apoptosis. Am. J. Pathol. 2000;157:1415&#x2013;1430. doi: 10.1016/S0002-9440(10)64779-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64779-7</ArticleId><ArticleId IdType="pmc">PMC1885741</ArticleId><ArticleId IdType="pubmed">11073801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Dou S., Jiang Y., Chen J., Wang C., Cheng B. Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson&#x2019;s disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy. Brain Res. 2019;1715:203&#x2013;212. doi: 10.1016/j.brainres.2019.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.03.027</ArticleId><ArticleId IdType="pubmed">30914252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Gao W., Shan X., Wang C., Wang H., Shao Z., Dou S., Jiang Y., Wang C., Cheng B. Apelin-36 mediates neuroprotective effects by regulating oxidative stress, autophagy and apoptosis in MPTP-induced Parkinson&#x2019;s disease model mice. Brain Res. 2020;1726:146493. doi: 10.1016/j.brainres.2019.146493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146493</ArticleId><ArticleId IdType="pubmed">31586624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Luo X., Liu X., Liu D., Wang X., Guo Z., Zhu L., Tian Q., Yang X., Wang J.-Z. Intraperitoneal administration of a novel TAT-BDNF peptide ameliorates cognitive impairments via modulating multiple pathways in two Alzheimer&#x2019;s rodent models. Sci. Rep. 2015;5:1&#x2013;14. doi: 10.1038/srep15032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep15032</ArticleId><ArticleId IdType="pmc">PMC4604491</ArticleId><ArticleId IdType="pubmed">26463268</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., Peng Q., Liu X., Jin J., Hou Z., Zhang J., Mori S., Ross C.A., Ye K., Duan W. Small-Molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington&#x2019;s disease. Hum. Mol. Genet. 2013;22:2462&#x2013;2470. doi: 10.1093/hmg/ddt098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt098</ArticleId><ArticleId IdType="pmc">PMC3658168</ArticleId><ArticleId IdType="pubmed">23446639</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Q., He W., Gayen M., Benoit M.R., Luo X., Hu X., Yan R. Activated CX3CL1/Smad2 signals prevent neuronal loss and Alzheimer&#x2019;s tau pathology-mediated cognitive dysfunction. J. Neurosci. 2020;40:1133&#x2013;1144. doi: 10.1523/JNEUROSCI.1333-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1333-19.2019</ArticleId><ArticleId IdType="pmc">PMC6989010</ArticleId><ArticleId IdType="pubmed">31822518</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnini S., Cantara S., Morbidelli L., Giachetti A., Ziche M. FGF-2 overexpression opposes the &#x3b2; amyloid toxic injuries to the vascular endothelium. Cell Death Differ. 2006;13:1088&#x2013;1096. doi: 10.1038/sj.cdd.4401803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401803</ArticleId><ArticleId IdType="pubmed">16410806</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsouri L., Ashraf A., Birch A.M., Lee K.K., Mirzaei N., Sastre M. Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice. Neurobiol. Aging. 2015;36:821&#x2013;831. doi: 10.1016/j.neurobiolaging.2014.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.004</ArticleId><ArticleId IdType="pubmed">25457554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou J.G., Cohen G., Mytilineou C. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: Involvement of the glutathione system. J. Neurochem. 1997;69:76&#x2013;83. doi: 10.1046/j.1471-4159.1997.69010076.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69010076.x</ArticleId><ArticleId IdType="pubmed">9202296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsuan S.-L., Klintworth H.M., Xia Z. Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. J. Neurosci. 2006;26:4481&#x2013;4491. doi: 10.1523/JNEUROSCI.4922-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4922-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674070</ArticleId><ArticleId IdType="pubmed">16641227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G., Chen G., Shi L., Feng J., Wang Y., Ye C., Feng W., Niu J., Huang Z. PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson&#x2019;s disease. Mol. Neurobiol. 2015;51:32&#x2013;42. doi: 10.1007/s12035-014-8750-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8750-5</ArticleId><ArticleId IdType="pubmed">24930088</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai P., Ye J., Zhu J., Liu D., Chen D., Wei X., Johnson N.R., Wang Z., Zhang H., Cao G., et al. Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effect of bFGF in the 6-OHDA-induced Parkinson&#x2019;s disease model. Aging Dis. 2016;7:336. doi: 10.14336/AD.2016.0117.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2016.0117</ArticleId><ArticleId IdType="pmc">PMC4963188</ArticleId><ArticleId IdType="pubmed">27493838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Xiong L., Wang G., Wan W., Zhong C., Zu H. Insulin-Like growth factor-1 protects SH-SY5Y cells against &#x3b2;-amyloid-induced apoptosis via the PI3K/Akt-Nrf2 pathway. Exp. Gerontol. 2017;87:23&#x2013;32. doi: 10.1016/j.exger.2016.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2016.11.009</ArticleId><ArticleId IdType="pubmed">27887985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Shu Y., Qu Y., Zhang L., Chu T., Zheng Y., Zhao H. C-myb Plays an Essential Role in the Protective Function of IGF-1 on Cytotoxicity Induced by A&#x3b2; 25&#x2013;35 via the PI3K/Akt Pathway. J. Mol. Neurosci. 2017;63:412&#x2013;418. doi: 10.1007/s12031-017-0991-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-017-0991-0</ArticleId><ArticleId IdType="pubmed">29110181</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F., Liu T., Meng S., Li F., Zhang Y., Jiang L. Insulin-Like Growth Factor-1 Alleviates Expression of A&#x3b2; 1&#x2013;40 and &#x3b1;-, &#x3b2;-, and &#x3b3;-Secretases in the Cortex and Hippocampus of APP/PS1 Double Transgenic Mice. J. Mol. Neurosci. 2018;66:595&#x2013;603. doi: 10.1007/s12031-018-1201-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1201-4</ArticleId><ArticleId IdType="pubmed">30414017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Li E., Park S. Insulin-Like growth factor-1 inhibits 6-hydroxydopamine-mediated endoplasmic reticulum stress-induced apoptosis via regulation of heme oxygenase-1 and Nrf2 expression in PC12 cells. Int. J. Neurosci. 2012;122:641&#x2013;649. doi: 10.3109/00207454.2012.702821.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2012.702821</ArticleId><ArticleId IdType="pubmed">22703470</ArticleId></ArticleIdList></Reference><Reference><Citation>El Ayadi A., Zigmond M.J., Smith A.D. IGF-1 protects dopamine neurons against oxidative stress: Association with changes in phosphokinases. Exp. Brain Res. 2016;234:1863&#x2013;1873. doi: 10.1007/s00221-016-4572-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-016-4572-1</ArticleId><ArticleId IdType="pmc">PMC4893922</ArticleId><ArticleId IdType="pubmed">26894890</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert S., Bryson E.A., Cordeli&#xe8;res F.P., Connors N.C., Datta S.R., Finkbeiner S., Greenberg M.E., Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington&#x2019;s disease and involves Huntingtin phosphorylation by Akt. Dev. Cell. 2002;2:831&#x2013;837. doi: 10.1016/S1534-5807(02)00188-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1534-5807(02)00188-0</ArticleId><ArticleId IdType="pubmed">12062094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 2008;16:1056&#x2013;1064. doi: 10.1038/mt.2008.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.60</ArticleId><ArticleId IdType="pmc">PMC2737251</ArticleId><ArticleId IdType="pubmed">18388910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y., Duan W., Liu Y., Liu Y., Liu C., Li Y., Wen D., Li Z., Li C. IGF1 affects macrophage invasion and activation and TNF-&#x3b1; production in the sciatic nerves of female SOD1G93A mice. Neurosci. Lett. 2018;668:1&#x2013;6. doi: 10.1016/j.neulet.2017.12.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.12.062</ArticleId><ArticleId IdType="pubmed">29294332</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wen D., Duan W., Yin J., Cui C., Wang Y., Li Z., Liu Y., Li C. Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway. Brain Res. Bull. 2018;139:203&#x2013;210. doi: 10.1016/j.brainresbull.2018.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.02.015</ArticleId><ArticleId IdType="pubmed">29499331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Li H., Wang H., Wang J.-H., Song F., Sun Y. Irisin exerts neuroprotective effects on cultured neurons by regulating astrocytes. Mediat. Inflamm. 2018;2018 doi: 10.1155/2018/9070341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/9070341</ArticleId><ArticleId IdType="pmc">PMC6178172</ArticleId><ArticleId IdType="pubmed">30356412</ArticleId></ArticleIdList></Reference><Reference><Citation>Heck S., Lezoualc&#x2019;h F., Engert S., Behl C. Insulin-Like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor &#x3ba;B. J. Biol. Chem. 1999;274:9828&#x2013;9835. doi: 10.1074/jbc.274.14.9828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.14.9828</ArticleId><ArticleId IdType="pubmed">10092673</ArticleId></ArticleIdList></Reference><Reference><Citation>Offen D., Shtaif B., Hadad D., Weizman A., Melamed E., Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: Possible implications for Parkinson&#x2019;s disease. Neurosci. Lett. 2001;316:129&#x2013;132. doi: 10.1016/S0304-3940(01)02344-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02344-8</ArticleId><ArticleId IdType="pubmed">11744219</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida R.D., Manadas B.J., Melo C.V., Gomes J.R., Mendes C.S., Gr&#xe3;os M.M., Carvalho R.F., Carvalho A.P., Duarte C.B. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 2005;12:1329&#x2013;1343. doi: 10.1038/sj.cdd.4401662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401662</ArticleId><ArticleId IdType="pubmed">15905876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Deng W., Gage F.H. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132:645&#x2013;660. doi: 10.1016/j.cell.2008.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.01.033</ArticleId><ArticleId IdType="pubmed">18295581</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H., Shubert T., Zhao C., Gage F.H. Exercise enhances learning and hippocampal neurogenesis in aged mice. J. Neurosci. 2005;25:8680&#x2013;8685. doi: 10.1523/JNEUROSCI.1731-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1731-05.2005</ArticleId><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao Y.-H., Hung H.-C., Chen S.-H., Gean P.-W. Social interaction rescues memory deficit in an animal model of Alzheimer&#x2019;s disease by increasing BDNF-dependent hippocampal neurogenesis. J. Neurosci. 2014;34:16207&#x2013;16219. doi: 10.1523/JNEUROSCI.0747-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0747-14.2014</ArticleId><ArticleId IdType="pmc">PMC6608495</ArticleId><ArticleId IdType="pubmed">25471562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-C., Lien C.-C., Hou W.-H., Chiang P.-M., Tsai K.-J. Gain of BDNF function in engrafted neural stem cells promotes the therapeutic potential for Alzheimer&#x2019;s disease. Sci. Rep. 2016;6:1&#x2013;16. doi: 10.1038/srep27358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep27358</ArticleId><ArticleId IdType="pmc">PMC4893631</ArticleId><ArticleId IdType="pubmed">27264956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho K.S., Lee J.H., Cho J., Cha G.-H., Song G.J. Autophagy modulators and neuroinflammation. Curr. Med. Chem. 2020;27:955&#x2013;982. doi: 10.2174/0929867325666181031144605.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867325666181031144605</ArticleId><ArticleId IdType="pubmed">30381067</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., Ransohoff R.M., et al. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol. 2015;14:388&#x2013;405. doi: 10.1016/S1474-4422(15)70016-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)70016-5</ArticleId><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R.M. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777&#x2013;783. doi: 10.1126/science.aag2590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson M., Lexell J., Deierborg T. Effects of physical exercise on neuroinflammation, neuroplasticity, neurodegeneration, and behavior: What we can learn from animal models in clinical settings. Neurorehabil. Neural Repair. 2015;29:577&#x2013;589. doi: 10.1177/1545968314562108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1545968314562108</ArticleId><ArticleId IdType="pubmed">25527485</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielman L.J., Little J.P., Klegeris A. Physical activity and exercise attenuate neuroinflammation in neurological diseases. Brain Res. Bull. 2016;125:19&#x2013;29. doi: 10.1016/j.brainresbull.2016.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2016.03.012</ArticleId><ArticleId IdType="pubmed">27021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechanover A., Kwon Y.T. Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies. Exp. Mol. Med. 2015;47:e147. doi: 10.1038/emm.2014.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2014.117</ArticleId><ArticleId IdType="pmc">PMC4351408</ArticleId><ArticleId IdType="pubmed">25766616</ArticleId></ArticleIdList></Reference><Reference><Citation>He C., Sumpter R., Jr., Levine B. Exercise induces autophagy in peripheral tissues and in the brain. Autophagy. 2012;8:1548&#x2013;1551. doi: 10.4161/auto.21327.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.21327</ArticleId><ArticleId IdType="pmc">PMC3463459</ArticleId><ArticleId IdType="pubmed">22892563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuede C.M., Zimmerman S.D., Dong H., Kling M.J., Bero A.W., Holtzman D.M., Timson B.F., Csernansky J.G. Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer&#x2019;s disease. Neurobiol. Dis. 2009;35:426&#x2013;432. doi: 10.1016/j.nbd.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.06.002</ArticleId><ArticleId IdType="pmc">PMC2745233</ArticleId><ArticleId IdType="pubmed">19524672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W., Barkow J.C., Freed C.R. Running wheel exercise reduces &#x3b1;-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson&#x2019;s disease. PLoS ONE. 2017;12:e0190160. doi: 10.1371/journal.pone.0190160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0190160</ArticleId><ArticleId IdType="pmc">PMC5741244</ArticleId><ArticleId IdType="pubmed">29272304</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang K.Y., Mintun M.A., Fagan A.M., Goate A.M., Bugg J.M., Holtzman D.M., Morris J.C., Head D. Exercise and Alzheimer&#x2019;s disease biomarkers in cognitively normal older adults. Ann. Neurol. 2010;68:311&#x2013;318. doi: 10.1002/ana.22096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22096</ArticleId><ArticleId IdType="pmc">PMC2936720</ArticleId><ArticleId IdType="pubmed">20818789</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Woosley A.N., Sivalingam N., Natarajan S., Howe P.H. Cathepsin-B-mediated cleavage of Disabled-2 regulates TGF-&#x3b2;-induced autophagy. Nat. Cell Biol. 2016;18:851&#x2013;863. doi: 10.1038/ncb3388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3388</ArticleId><ArticleId IdType="pmc">PMC5937135</ArticleId><ArticleId IdType="pubmed">27398911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G.H., Kim J.E., Rhie S.J., Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 2015;24:325. doi: 10.5607/en.2015.24.4.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.4.325</ArticleId><ArticleId IdType="pmc">PMC4688332</ArticleId><ArticleId IdType="pubmed">26713080</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-S&#xe1;mano M.&#xc1;., Grajales-G&#xf3;mez M., Zuarth-V&#xe1;zquez J.M., Navarro-Flores M.F., Mart&#xed;nez-Saavedra M., Ju&#xe1;rez-Le&#xf3;n &#xd3;.A., Morales-Garc&#xed;a M.G., Enr&#xed;quez-Estrada V.M., G&#xf3;mez-P&#xe9;rez F.J., Cuevas-Ramos D. Fibroblast growth factor 21 and its novel association with oxidative stress. Redox Biol. 2017;11:335&#x2013;341. doi: 10.1016/j.redox.2016.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2016.12.024</ArticleId><ArticleId IdType="pmc">PMC5200873</ArticleId><ArticleId IdType="pubmed">28039838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom G.S. Amyloid-&#x3b2; and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505&#x2013;508. doi: 10.1001/jamaneurol.2013.5847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.5847</ArticleId><ArticleId IdType="pubmed">24493463</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D., Pottier C., Nicolas G., Le Guennec K., Rovelet-Lecrux A. Alzheimer disease: Modeling an A&#x3b2;-centered biological network. Mol. Psychiatry. 2016;21:861&#x2013;871. doi: 10.1038/mp.2016.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2016.38</ArticleId><ArticleId IdType="pubmed">27021818</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohe M., Synowitz M., Glass R., Paul S.M., Nykjaer A., Willnow T.E. Brain-Derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J. Neurosci. 2009;29:15472&#x2013;15478. doi: 10.1523/JNEUROSCI.3960-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3960-09.2009</ArticleId><ArticleId IdType="pmc">PMC6666105</ArticleId><ArticleId IdType="pubmed">20007471</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen K.T., Adlerz L., Multhaup G., Iverfeldt K. Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-&#x3b2; precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. J. Biol. Chem. 2010;285:10223&#x2013;10231. doi: 10.1074/jbc.M109.038224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.038224</ArticleId><ArticleId IdType="pmc">PMC2856227</ArticleId><ArticleId IdType="pubmed">20139073</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr O., Schilbach K., Moll L., Hettich M.M., Freude S., Wunderlich F.T., Ernst M., Zemva J., Br&#xfc;ning J.C., Krone W., et al. Insulin receptor signaling mediates APP processing and &#x3b2;-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer&#x2019;s disease. Age. 2013;35:83&#x2013;101. doi: 10.1007/s11357-011-9333-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-011-9333-2</ArticleId><ArticleId IdType="pmc">PMC3543743</ArticleId><ArticleId IdType="pubmed">22057897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 2009;15:112&#x2013;119. doi: 10.1016/j.molmed.2009.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2009.01.003</ArticleId><ArticleId IdType="pubmed">19246243</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott E., Atlas R., Lange A., Ginzburg I. Brain-Derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3Kinase signalling mechanism. Eur. J. Neurosci. 2005;22:1081&#x2013;1089. doi: 10.1111/j.1460-9568.2005.04290.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2005.04290.x</ArticleId><ArticleId IdType="pubmed">16176349</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785&#x2013;789. doi: 10.1038/378785a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/378785a0</ArticleId><ArticleId IdType="pubmed">8524413</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford K.I., Middelbeek R.J.W., Goodyear L.J. Exercise effects on white adipose tissue: Beiging and metabolic adaptations. Diabetes. 2015;64:2361&#x2013;2368. doi: 10.2337/db15-0227.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db15-0227</ArticleId><ArticleId IdType="pmc">PMC4477356</ArticleId><ArticleId IdType="pubmed">26050668</ArticleId></ArticleIdList></Reference><Reference><Citation>Seldin M.M., Peterson J.M., Byerly M.S., Wei Z., Wong G.W. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J. Biol. Chem. 2012;287:11968&#x2013;11980. doi: 10.1074/jbc.M111.336834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.336834</ArticleId><ArticleId IdType="pmc">PMC3320944</ArticleId><ArticleId IdType="pubmed">22351773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-H., Bassel-Duby R., Olson E.N. Heart-and muscle-derived signaling system dependent on MED13 and Wingless controls obesity in Drosophila. Proc. Natl. Acad. Sci. USA. 2014;111:9491&#x2013;9496. doi: 10.1073/pnas.1409427111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1409427111</ArticleId><ArticleId IdType="pmc">PMC4084481</ArticleId><ArticleId IdType="pubmed">24979807</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen B.K. The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk. J. Physiol. 2009;587:5559&#x2013;5568. doi: 10.1113/jphysiol.2009.179515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2009.179515</ArticleId><ArticleId IdType="pmc">PMC2805368</ArticleId><ArticleId IdType="pubmed">19752112</ArticleId></ArticleIdList></Reference><Reference><Citation>de Luis D.A., Aller R., Izaola O., Primo D., Romero E. rs10767664 gene variant in brain-derived neurotrophic factor is associated with diabetes mellitus type 2 in Caucasian females with obesity. Ann. Nutr. Metab. 2017;70:286&#x2013;292. doi: 10.1159/000474956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000474956</ArticleId><ArticleId IdType="pubmed">28595187</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwa M., Kishimoto H., Nofuji Y., Nakano H., Sasaki H., Radak Z., Kumagai S. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism. 2006;55:852&#x2013;857. doi: 10.1016/j.metabol.2006.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2006.02.012</ArticleId><ArticleId IdType="pubmed">16784955</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida A., Nonomura T., Nakagawa T., Itakura Y., Ono-Kishino M., Yamanaka M., Sugaru E., Taiji M., Noguchi H. Brain-Derived neurotrophic factor ameliorates lipid metabolism in diabetic mice. Diabetes Obes. Metab. 2002;4:262&#x2013;269. doi: 10.1046/j.1463-1326.2002.00206.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1463-1326.2002.00206.x</ArticleId><ArticleId IdType="pubmed">12099975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q., Liu X., Glazier B.J., Krolick K.N., Yang S., He J., Lo C.C., Shi H. Differential sympathetic activation of adipose tissues by brain-derived neurotrophic factor. Biomolecules. 2019;9:452. doi: 10.3390/biom9090452.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom9090452</ArticleId><ArticleId IdType="pmc">PMC6769916</ArticleId><ArticleId IdType="pubmed">31492038</ArticleId></ArticleIdList></Reference><Reference><Citation>Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPAR&#x3b1; and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426&#x2013;437. doi: 10.1016/j.cmet.2007.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2007.05.002</ArticleId><ArticleId IdType="pubmed">17550778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao Y.-C., Ho P.-C., Tu Y.-K., Jou I., Tsai K.-J. Lipids and Alzheimer&#x2019;s disease. Int. J. Mol. Sci. 2020;21:1505. doi: 10.3390/ijms21041505.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21041505</ArticleId><ArticleId IdType="pmc">PMC7073164</ArticleId><ArticleId IdType="pubmed">32098382</ArticleId></ArticleIdList></Reference><Reference><Citation>Xicoy H., Wieringa B., Martens G.J.M. The role of lipids in Parkinson&#x2019;s disease. Cells. 2019;8:27. doi: 10.3390/cells8010027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8010027</ArticleId><ArticleId IdType="pmc">PMC6356353</ArticleId><ArticleId IdType="pubmed">30621069</ArticleId></ArticleIdList></Reference><Reference><Citation>Suriano F., Van Hul M., Cani P.D. Gut microbiota and regulation of myokine-adipokine function. Curr. Opin. Pharmacol. 2020;52:9&#x2013;17. doi: 10.1016/j.coph.2020.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2020.03.006</ArticleId><ArticleId IdType="pubmed">32388413</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung T.C., Olson C.A., Hsiao E.Y. Interactions between the microbiota, immune and nervous systems in health and disease. Nat. Neurosci. 2017;20:145. doi: 10.1038/nn.4476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4476</ArticleId><ArticleId IdType="pmc">PMC6960010</ArticleId><ArticleId IdType="pubmed">28092661</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheperjans F., Aho V., Pereira P.A.B., Koskinen K., Paulin L., Pekkonen E., Haapaniemi E., Kaakkola S., Eerola-Rautio J., Pohja M., et al. Gut microbiota are related to Parkinson&#x2019;s disease and clinical phenotype. Mov. Disord. 2015;30:350&#x2013;358. doi: 10.1002/mds.26069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26069</ArticleId><ArticleId IdType="pubmed">25476529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson T.R., Debelius J.W., Thron T., Janssen S., Shastri G.G., Ilhan Z.E., Challis C., Schretter C.E., Rocha S., Gradinaru V., et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson&#x2019;s disease. Cell. 2016;167:1469&#x2013;1480. doi: 10.1016/j.cell.2016.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri S., Kim H., Garcia-Perez I., Reza M.M., Martin K.A., Kundu P., Cox L.M., Selkrig J., Posma J.M., Zhang H., et al. The gut microbiota influences skeletal muscle mass and function in mice. Sci. Transl. Med. 2019;11:eaan5662. doi: 10.1126/scitranslmed.aan5662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan5662</ArticleId><ArticleId IdType="pmc">PMC7501733</ArticleId><ArticleId IdType="pubmed">31341063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.J., Russo-Neustadt A.A. Running exercise-and antidepressant-induced increases in growth and survival-associated signaling molecules are IGF-dependent. Growth Factors. 2007;25:118&#x2013;131. doi: 10.1080/08977190701602329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08977190701602329</ArticleId><ArticleId IdType="pubmed">17852404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai T.-T., Wang B., Xiao Z.-Y., You Y., Tian S.-W. Apelin-13 upregulates BDNF against chronic stress-induced depression-like phenotypes by ameliorating HPA axis and hippocampal glucocorticoid receptor dysfunctions. Neuroscience. 2018;390:151&#x2013;159. doi: 10.1016/j.neuroscience.2018.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.08.018</ArticleId><ArticleId IdType="pubmed">30170158</ArticleId></ArticleIdList></Reference><Reference><Citation>Henningsen J., Rigbolt K.T.G., Blagoev B., Pedersen B.K., Kratchmarova I. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol. Cell. Proteom. 2010;9:2482&#x2013;2496. doi: 10.1074/mcp.M110.002113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M110.002113</ArticleId><ArticleId IdType="pmc">PMC2984231</ArticleId><ArticleId IdType="pubmed">20631206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelke C., Dziewas R., Minnerup J., Meuth S.G., Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine. 2019;49:381&#x2013;388. doi: 10.1016/j.ebiom.2019.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.10.034</ArticleId><ArticleId IdType="pmc">PMC6945275</ArticleId><ArticleId IdType="pubmed">31662290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Wang L., You W., Shan T. Myokines mediate the cross talk between skeletal muscle and other organs. J. Cell. Physiol. 2021;236:2393&#x2013;2412. doi: 10.1002/jcp.30033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.30033</ArticleId><ArticleId IdType="pubmed">32885426</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., J&#xe4;ggi F., Wolburg H., Gengler S., et al. A&#x3b2;42-Driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards J.G., Higgins G.A., Ouagazzal A.-M., Ozmen L., Kew J.N.C., Bohrmann B., Malherbe P., Brockhaus M., Loetscher H., Czech C., et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci. 2003;23:8989&#x2013;9003. doi: 10.1523/JNEUROSCI.23-26-08989.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-26-08989.2003</ArticleId><ArticleId IdType="pmc">PMC6740398</ArticleId><ArticleId IdType="pubmed">14523101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozmen L., Albientz A., Czech C., Jacobsen H. Expression of transgenic APP mRNA is the key determinant for &#x3b2;-amyloid deposition in PS2APP transgenic mice. Neurodegener. Dis. 2009;6:29&#x2013;36. doi: 10.1159/000170884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000170884</ArticleId><ArticleId IdType="pubmed">19066434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, A&#x3b2; elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;103. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.-H., Mistl C., Rothacher S., Ledermann B., B&#xfc;rki K., Frey P., Paganetti P.A., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA. 1997;94:13287&#x2013;13292. doi: 10.1073/pnas.94.24.13287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.24.13287</ArticleId><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L., Masliah E., Yu G.-Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-Level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 2000;20:4050&#x2013;4058. doi: 10.1523/JNEUROSCI.20-11-04050.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-11-04050.2000</ArticleId><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Musar&#xf2; A., McCullagh K., Paul A., Houghton L., Dobrowolny G., Molinaro M., Barton E.R., Sweeney H.L., Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 2001;27:195&#x2013;200. doi: 10.1038/84839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/84839</ArticleId><ArticleId IdType="pubmed">11175789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999;8:397&#x2013;407. doi: 10.1093/hmg/8.3.397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.3.397</ArticleId><ArticleId IdType="pubmed">9949199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y., Higuchi M., Zhang B., Huang S.-M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M.-Y. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.-X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D., Lasrado R., Snauwaert J., Vandeweert E., Van Haesendonck C., Borghgraef P., Van Leuven F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem. 2005;280:3963&#x2013;3973. doi: 10.1074/jbc.M409876200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M409876200</ArticleId><ArticleId IdType="pubmed">15509565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>